



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. DR AB Xuma Building, 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA 0187
Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: tenders@health.gov.za

Ref: HP09-2026SD

HP09-2026SD: SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2026 TO 30 APRIL 2029

1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified, e.g., price per single unit, as per specification.
4. The following provincial Departments of Health will participate in this contract:

PARTICIPANTS	CONTACT PERSON	TEL NO	E-MAIL
Eastern Cape (PE Depot)	Mr D Martin	(041) 406-9815	deon.martin@echealth.gov.za
Eastern Cape (Mthatha Depot)	Ms M Morrow	(083) 240 3351	merlen.morrow@echealth.gov.za
Free State	Mr TW Khetsekile	(051) 411 0578	khetsekitw@fshealth.gov.za
Gauteng	Mr S Langa	(066) 305 8842	simthembile.langa@gauteng.gov.za
KwaZulu-Natal	Ms T Njapha	(031) 469-8300	thandeka.njapha@kznhealth.gov.za
Limpopo	Mr M Moila	(015) 223-9000	makutu.moila@dhsd.limpopo.gov.za
Mpumalanga	Ms M Moloto	(013) 283-9000	margarettmm@mpuhealth.gov.za
North West	Ms D Moswele	(018) 384-4838	ddmoswele@nwpg.gov.za
Northern Cape	Ms E Delpont	(053) 830-2717	edelpont@ncpg.gov.za
Western Cape	Mr N Mia	(021) 483-5800	nisaar.mia@westerncape.gov.za
South African Military Health Services	Lt Col I Oberholster	(012) 355-4096	samhsproc.pharma@gmail.com
Correctional Services	Ms T Matsitse	(012) 307-2310	tammy.links@dcs.gov.za

K JAMALOODIEN
CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT
For: DIRECTOR-GENERAL: HEALTH
DATE: 2 April 2026



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

HP09-2026SD: SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2026 TO 30 APRIL 2029

1. IMPORTANT GENERAL INFORMATION

- 1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.
- 1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
- 1.3 All prices are inclusive of 15 % VAT.
- 1.4 All prices are on a delivered basis.
- 1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAILS

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Abbott Laboratories SA (Pty) Ltd	MAAA0030395	V2150	219 Golf Club Terrace Constantia Kloof ROODEPOORT 1709	Ms Smith	010 017 6453 060 579 7944	maxine.smith@abbott.com
Acino Pharma (Pty) Ltd	MAAA0009244	VGS73	No. 106, 16th Road MIDRAND 1686	Mr Reddy	011 516 1700 066 304 6900	state_za@arceralifesciences.com

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Activo Health (Pty) Ltd	MAAA0391119	V32D3	Block B, 272 West Avenue Arena Office Park CENTURION 0157	Ms Booysen	021 943 0600 082 979 5868	rpactive@activo.co.za
Arya Pharma (Pty) Ltd	MAAA0717051	VF6A8	Corner Barbara and North Reef Road Elandsfontein GERMISTON 1601	Mrs Frazer	010 060 0741 061 472 1568	chantelle@aryapharma.co.za
Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	7th Floor, Sandton City Office Towers 83 Rivonia Road and 5th street SANDTON 2196	Mr Labuschagne	010 276 0037 082 897 3611	deon.labuschagne@alkem.com
Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	Po Box 343 PARKLANDS 2121	Mr Bhaskar Mr Murthy	011 867 9100 072 226 9143	vijaya.bhaskar@aurobindo.com
Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	1 Sherborne Road PARKTOWN 2193	Mr Mahomed	011 611 1600 083 633 8781	irefaanm@austell.co.za
Bayer (Pty) Ltd	MAAA0009623	V6390	PO Box 143 ISANDO 1600	Ms Noack Ms Harvey	011 921 5279	za_tenders@bayer.com
Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	PO Box 32003 Mobeni DURBAN 4052	Mr Maritz	011 315 9150 082 887 4926	willem.maritz@cipla.com
Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Woodmead North Office Park Block S, Second Floor 54 Maxwell Drive WOODMEAD 2191	Mr Mothilal	011 324 2100 060 528 0656	rashemmothilal@drreddys.com

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Emcure Pharmaceuticals SA (Pty) Ltd	MAAA0050669	V3GQ7	PO Box 2099 MONDEOR 2110	Mr Maleke	011 867 7274 082 570 5978	peane.maleke@emcure.com
Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	100 Sovereign Drive Route 21 Corporate Park Nellmapius Drive IRENE 0157	Mr Bouwer	012 345 1747 082 879 8866	carel@equitypharma.co.za
Ferring (Pty) Ltd	MAAA0005879	VXY92	Route 21 Corporate Park 6 Regency Drive IRENE 0014	Ms Tippett	012 443 4307 083 303 4252	chanelle.tippett@ferring.com
Forrester Pharma (Pty) Ltd	MAAA0090397	V3UR7	2 Waterford Mews Waterford Place Century City CAPE TOWN 7441	Mrs Booysen	021 943 0600 082 979 5868	fatima.booyesen@forresterpharma.com
Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	PO Box 1523 DURBAN 4000	Mr Moonsamy	031 538 8700 083 779 1321	kevinm@gulfdrug.co.za
Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Waterfall Corporate Campus Building 2, First Floor 74 Waterfall Drive MIDRAND 2066	Mr Johnson	012 644 1220 082 388 7226	johnson.n@hetero.com
Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	PO Box 777 Kelvin SANDRINGHAM 2054	Ms Job	086 999 0912 082 901 8729	grace.j@innovata.co.za
Ipharma (Pty) Ltd	MAAA0003048	V8QU8	Postnet 319 Private Bag X1007 LYTTELTON 0140	Ms Hime	011 314 2366 083 258 6226	natalie@ipharma.co.za

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	72 Steel Road SPARTAN 1619	Mr Saloojee Ms Friedman	010 329 0704 010 329 0647 083 348 6000	farid.saloojee@kiarahealth.com tanya.friedman@kiarahealth.com
LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	N4 Gateway Industrial Park, 33 Ghaap Street WILLOW PARK MANOR 0184	Mr Montjane	012 004 1360 082 898 9723	mareka@lhcpharma.com
Mundipharma (Pty) Ltd	MAAA0228483	V32G6	Block D, Grosvenor Square Park Lane Century City CAPE TOWN 7441	Mr Schoeman	021 671 5251 083 677 5722	buks.schoeman@mundipharma.co.za
Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	PO Box 12257 VORNA VALLEY 1686	Ms Nhlapo	011 347 6600 079 806 9363	rfq.sa@novartis.com gugulethu.nhlapo@novartis.com
Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	PO Box 421001 FORDSBURG 2033	Mr Bodhania	011 433 0602 083 325 3741	mbodhania@oethmaan.co.za
Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	PO Box 783720 SANDTON 2196	Mr Mnguni	011 320 6091 082 307 9658	themba.mnguni@pfizer.com
Pharmacare Limited	MAAA0008452	V2205	PO Box 1593 GALLO MANOR 2052	Mr Ajodapersad	010 592 1590 082 356 5314	aajodapersad@aspenspharma.com
Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	PO Box 786522 SANDTON 2146	Mr King	011 784 0077 082 448 3939	gary.king@pharmaco.co.za
Portfolio Pharmaceuticals (Pty) Ltd	MAAA0039590	VWB81	PO Box 463 MARAISBURG 1700	Ms McDowall	011 334 5530 082 898 8087	bernie@portfoliosa.co.za
Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	PO Box 43486 INDUSTRIA 2042	Mr Mboniswa	012 643 2000 072 012 1769	monwabisi.mboniswa@sunpharma.com

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Resmed Healthcare CC	MAAA0010098	VCEJ2	PO Box 65409 RESERVOIR HILLS 4090	Mr Singh	031 577 7258 082 775 5027	lal@resmed.co.za
Ruby Pharmaceuticals (Pty) Ltd	MAAA0562340	VG1F0	1st Floor Pharos House 70 Buckingham Terrace WESTVILLE 3629	Mr Ghoor	031 003 5132 072 213 7533	arshad@rubypharma.co.za
Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Magwa Crescent West Waterfall City JUKSKEI VIEW 2090	Ms Moodley	010 070 1614 083 704 1806	tenders-1.sandoz@sandoz.com
Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	Private Bag X207 MIDRAND 1685	Mr Davis	011 256 3700 082 449 9876	jerome.davis@sanofi.com jean-baptiste.bregeon@sanofi.com
Smart Pharmaceuticals (Pty) Ltd	MAAA1003704	V2CW0	Private X3 GLOSDERRY 7702	Mr Mohamed	021 987 3621 082 953 5640	nawaalmatthews0@gmail.com
Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VSSS4	PO Box 8356 MIDRAND 1685	Ms Simaan Ms Rudman	082 449 5995 073 409 0000	gaby.simaan@trinitypharma.co.za claire.rudman@trinitypharma.co.za
Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	PO Box 653590 BENMORE 2010	Mr Elston	011 055 0220 063 619 8690	andrew.elston@teva.co.za
Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	PO Box 68687 BRYANSTON 2021	Ms Simaan Ms Rudman	082 449 5995 073 409 0000	gaby.simaan@trinitypharma.co.za claire.rudman@trinitypharma.co.za
Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Corner Birch Road and Bluegum Avenue Anchorville LENASIA 1827	Mr Bera	012 749 1373 083 647 7860	arshad@unimedhealthcare.co.za

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	4 Brewery Street Kempton Park ISANDO 1600	Mr Ekhambaram	011 451 1300 071 473 3900	kumaraswamy.ekhambaram@viatrix.com
Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Suite 100 Private Bag X32 Highveld Park CENTURION 0169	Ms Venter Ms Nkosi	012 748 6400 082 416 6996	rhoda.venter@zydus.co.za dudu.nkosi@zydus.co.za

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
6	Acetylcysteine 600mg tablet; 10 tablets	Procurement class 1	Pack of 10 tablets	290 386		290 386	100.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Amuco 600	R39.67	Pack of 10 tablets	14	5	90.00	222001845	CO
7	Acitretin 10mg capsule; 28/30 capsules		Pack of 28/30 capsules	6 316		6 316	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	NEOTIGASON 10 mg	R609.60	Pack of 30 capsules	14	3	90.00	180179717	CO
8	Acitretin 25mg capsule; 28/30 capsules		Pack of 28/30 capsules	14 556		14 556	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	NEOTIGASON 25 mg	R1 419.69	Pack of 30 capsules	14	2	90.00	180179725	CO
11	Alfacalcidol 0,25mcg capsule; 28/30 capsules		Pack of 28/30 capsules	212 080		212 080	100.00%	Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VSSS4	ZODORAY 0,25 µg	R67.28	Pack of 30 capsules	14	135	90.00	189712166	CO
12	Alfacalcidol 1mcg capsule; 28/30 capsules		Pack of 28/30 capsules	56 548		56 548	100.00%	Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VSSS4	ZODORAY 1 µg	R224.02	Pack of 30 capsules	14	135	90.00	189714139	CO
14	Allopurinol 100mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 148 600		1 148 600	100.00%	Forrester Pharma (Pty) Ltd	MAAA0090397	V3UR7	Zorikos 100	R8.59	Pack of 30 tablets	14	50	90.00	222001078	CO
15	Allopurinol 100mg tablet; 56/60 tablets		Pack of 56/60 tablets	453 579		453 579	100.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Allopurinol 100	R14.64	Pack of 56 tablets	14	10	90.00	181934797	CO
16	Allopurinol 300mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 981 830		1 981 830	100.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Allopurinol 300	R16.92	Pack of 30 tablets	14	10	90.00	180339396	PG
17	Alprazolam 0,5mg tablet; 30 tablets		Pack of 30 tablets	71 831		71 831	100.00%	Pharmacare Limited	MAAA0008452	V2205	AZOR TABS 0.5MG 30'S	R15.94	Pack of 30 tablets	14	60	90.00	189714591	CO
18	Amiodarone 200mg tablet; 28/30 tablets		Pack of 28/30 tablets	70 934		70 934	100.00%	Ipharma (Pty) Ltd	MAAA0003048	V8QU8	Myorythm 200	R34.00	Pack of 30 tablets	14	336	96.00	189710641	CO
19	Amisulpiride 200mg tablet; 28/30 tablets		Pack of 28/30 tablets	584 982		584 982	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	PRAMISUL 200 mg	R150.10	Pack of 30 tablets	14	1 Pack	90.00	181807812	CO
20	Amisulpiride 50mg tablet; 28/30 tablets		Pack of 28/30 tablets	184 860		184 860	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	PRAMISUL 50 mg	R74.77	Pack of 30 tablets	14	1 Pack	90.00	181807811	CO
21	Amitriptyline 10mg tablet; 100 tablets		Pack of 100 tablets	43 560		43 560	100.00%	Pharmacare Limited	MAAA0008452	V2205	TREPILINE 10MG TABS 100'S	R26.86	Pack of 100 tablets	14	35	81.53	189710133	CO
22	Amitriptyline 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	2 848 662		2 848 662	100.00%	Pharmacare Limited	MAAA0008452	V2205	TREPILINE TABS 10MG 28'S BB	R4.59	Pack of 28 tablets	14	160	90.00	180339402	PG
23	Amitriptyline 25mg tablet; 100 tablets		Pack of 100 tablets	160 510		160 510	100.00%	Pharmacare Limited	MAAA0008452	V2205	TREPILINE 25MG TABS 100'S	R16.29	Pack of 100 tablets	14	60	90.00	189760812	BT
24	Amitriptyline 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	9 228 867		3 139 189	34.01%	Pharmacare Limited	MAAA0008452	V2205	TREPILINE TABS 25MG 28 BB	R4.82	Pack of 28 tablets	14	100	90.00	189711829	CO
						3 061 058	33.17%	Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VSSS4	VEIKIRIN 25	R4.94	Pack of 30 tablets	14	36	87.76		
						3 028 620	32.82%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF AMITRIPTYLINE 25	R4.99	Pack of 28 tablets	14	100	86.83		
25	Amitriptyline 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	578 813		231 525	40.00%	Pharmacare Limited	MAAA0008452	V2205	TREPILINE 25MG TAB 56 BB	R9.02	Pack of 56 tablets	14	60	90.00	189711830	CO
						347 288	60.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF AMITRIPTYLINE 25	R9.20	Pack of 56 tablets	14	50	88.20		
26	Amitriptyline 25mg tablet; 84/90 tablets		Pack of 84/90 tablets	192 266		192 266	100.00%	Pharmacare Limited	MAAA0008452	V2205	TREPILINE TABS 25MG 84'S BB	R13.61	Pack of 84 tablets	14	60	90.00	189711831	CO
27	Amlodipine 10mg tablet; 28/30 tablets	Class 2	Pack of 28/30 tablets	46 661 798		13 045 350	27.96%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Amlodipine 10 Unimed	R4.17	Pack of 28 tablets	14	200	96.24	181936074	CO
						12 640 055	27.09%	Smart Pharmaceuticals (Pty) Ltd	MAAA1003704	V2CW0	Vasloc 10mg	R4.39	Pack of 28 tablets	14	238	93.25		
						10 853 504	23.26%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Amlodipine 10mg	R4.63	Pack of 28 tablets	14	10	80.07		
						10 122 888	21.69%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	Ciplavasc 10	R4.88	Pack of 28 tablets	14	720	74.68		
28	Amlodipine 5mg tablet; 28/30 tablets	Class 1	Pack of 28/30 tablets	34 994 567	41 232 605	11 492 777	27.87%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Amlodipine 5 Unimed	R3.20	Pack of 28 tablets	14	300	96.24	181936075	CO
						11 098 698	26.92%	Smart Pharmaceuticals (Pty) Ltd	MAAA1003704	V2CW0	Vasloc 5mg	R3.38	Pack of 28 tablets	14	264	92.94		
						9 539 100	23.13%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	Ciplavasc 5	R3.56	Pack of 28 tablets	14	720	79.88		
						9 102 031	22.07%	Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Amlodac 5	R3.69	Pack of 30 tablets	14	100	76.22		
32	Aripiprazole 10mg tablet; 30 tablets		Pack of 30 tablets	33 406		33 406	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Apize 10 mg	R11.90	Pack of 30 tablets (3 x 10)	14	1	90.00	181807310	CO
33	Aripiprazole 15mg tablet; 30 tablets		Pack of 30 tablets	21 540		21 540	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Apize 15 mg	R20.94	Pack of 30 tablets (3 x 10)	14	1	90.00	181807313	CO
34	Aripiprazole 5mg tablet; 30 tablets		Pack of 30 tablets	26 512		26 512	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Apize 5 mg	R15.57	Pack of 30 tablets (3 x 10)	14	1	90.00	181869812	CO
36	Aspirin 300mg scored tablet; 14 tablets	Class 9	Pack of 14 tablets	42 314 347		11 579 654	27.37%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Aspirin 300 Unimed	R3.80	Pack of 14 tablets	14	300	96.24	222000916	CO
						11 489 414	27.15%	Resmed Healthcare CC	MAAA0010098	VCEJ2	Aspirin 300mg tablet	R3.85	Pack of 14 tablets	14	300	95.49		
						10 686 875	25.26%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF ASPIRIN 300mg	R3.85	Pack of 14 tablets	14	300	88.82		
						8 558 404	20.23%	Ipharma (Pty) Ltd	MAAA0003048	V8QU8	Dr du Toit's Pain Expeller	R4.85	Pack of 14 tablets	14	280	71.13		
37	Aspirin 300mg scored tablet; 96 tablets		Pack of 96 tablets	288 733		288 733	100.00%	Resmed Healthcare CC	MAAA0010098	VCEJ2	Aspirin 300mg tablet	R13.80	Pack of 96 tablets	14	100	96.67	189714405	CO
40	Atenolol 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	71 820		71 820	100.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Tenopress 25mg Tablets	R15.90	Pack of 28 tablets	14	10	90.00	222001081	CO
41	Atenolol 50mg tablet; 28/30 tablets	Class 15	Pack of 28/30 tablets	14 489 771		5 176 973	35.73%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Tenopress 50 mg Tablets	R3.78	Pack of 28 tablets	14	10	90.00	189710125	CO
						4 930 204	34.03%	Arya Pharma (Pty) Ltd	MAAA0717051	VF6A8	ATENOLOL 50 ARYA	R3.96	Pack of 28 tablets	14	500	85.71		
						4 382 595	30.25%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF ATENOLOL 50	R4.36	Pack of 28 tablets	14	300	76.19		
43	Atorvastatin 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 788 396		1 788 396	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Alipto 10	R6.18	Pack of 30 tablets	14	200	96.24	181798132	CO
46	Atorvastatin 40mg tablet; 30 tablets		Pack of 30 tablets	801 983		801 983	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Alipto 40	R17.81	Pack of 30 tablets	14	65	96.24	181859938	CO

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
47	Baclofen 10mg tablet; 30 tablets		Pack of 30 tablets	1 904 916		1 904 916	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	BACLOFEN 10 TEVA	R13.80	Pack of 30 tablets	14	144	90.00	189710127	CO
52	Bezafibrate 400mg tablet; 28/30 tablets	Class 13	Pack of 28/30 tablets	268 247		268 247	100.00%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	BEZAFIBRATE 400MG 30s	R65.50	Pack of 30 tablets	14	50	66.09	180000649	CO
55	Bromocriptine 2,5mg tablet; 28/30 tablets		Pack of 28/30 tablets	22 241		22 241	100.00%	Pharmacare Limited	MAAA0008452	V2205	ASPEN BROMOCRIPTINE 2.5MG 30'S	R95.45	Pack of 30 tablets	14	10	90.00	189710310	CO
56	Bupropion 150mg tablet; 30 tablets		Pack of 30 tablets	16 429		16 429	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	BUPROPION XL 150 mg AURO	R80.15	Pack of 30 tablets	14	3 Pack	90.00	222001425	CO
57	Bupropion 300mg tablet; 30 tablets		Pack of 30 tablets	12 901		12 901	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	BUPROPION XL 300 mg AURO	R79.56	Pack of 30 tablets	14	3 Pack	90.00	222001426	CO
58	Cabergoline 0,5mg tablet; 4 tablets		Pack of 4 tablets	70 610		70 610	100.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Dostinex 0.5mg TAB, 4s	R255.89	Pack of 4 tablets	14	1	90.00	180348494	CO
60	Calcium salt providing 168mg - 250mg elemental calcium, chewable tablet; 168 tablets		Pack of 168 tablets	1 748 772		1 748 772	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Calci Chew	R16.15	Pack of 168 tablets	14	40	90.00	222000440	CO
61	Calcium carbonate providing 500mg elemental calcium, soluble tablet; 10 tablets		Pack of 10 tablets	10 660 394		10 660 394	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	FIZZICAL	R8.03	Pack of 10 tablets	14	96	90.00	180964704	CO
62	Calcium carbonate providing 500mg elemental calcium, soluble tablet; 30 tablets		Pack of 30 tablets	11 878 214		11 878 214	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	FIZZICAL	R15.85	Pack of 30 tablets	14	40	90.00	181917243	CO
65	Captopril 25mg tablet; 60 tablets, scored		Pack of 60 tablets scored	28 765		28 765	100.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	MYLAN CAPTOPRIL 25	R13.01	Pack of 60 tablets scored	14	30	90.00	189710010	CO
67	Carbamazepine 200mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 799 781		861 225	47.85%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Partid - 200	R12.06	Pack of 28 tablets	14	100	96.20	181892375	PG
					938 556	938 556	52.15%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF CARBAMAZEPINE 200	R13.04	Pack of 28 tablets	14	100	82.69		
68	Carbamazepine 200mg tablet; 56/60 tablets		Pack of 56/60 tablets	2 876 938		2 301 550	80.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Partid - 200	R23.15	Pack of 56 tablets	14	70	96.20	180339414	PG
						575 388	20.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Carbamazepine 200 Unimed	R26.20	Pack of 56 tablets	14	100	84.38		
69	Carbamazepine 200mg tablet; 84/90 tablets		Pack of 84/90 tablets	1 461 001		1 168 801	80.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Partid - 200	R34.72	Pack of 84 tablets	14	50	96.20	180339437	PG
						292 200	20.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF CARBAMAZEPINE 200	R39.88	Pack of 84 tablets	14	100	76.62		
71	Carbidopa 25mg and Levodopa 100mg tablet; 100 tablets		Pack of 100 tablets	211 993		211 993	100.00%	Pharmacare Limited	MAAA0008452	V2205	CARBILEV TABS 25/100MG 100'S - TENDER	R120.05	Pack of 100 tablets	14	10	90.00	189710283	CO
73	Carbimazole 5mg tablet; 100 tablets		Pack of 100 tablets	343 527		343 527	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Carbifora 5	R64.38	Pack of 100 tablets	14	50	95.21	222000144	CO
74	Carbimazole 20mg tablet; 100 tablets		Pack of 100 tablets	18 600		18 600	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Carbifora 20	R125.10	Pack of 100 tablets	14	50	96.24	222001847	CO
75	Carvedilol 12,5mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	2 579 379		1 547 627	60.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Rubitrend 12,5	R8.20	Pack of 28 tablets	14	50	83.78	222001084	CO
						1 031 752	40.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	Carloc 12,5	R8.52	Pack of 30 tablets	14	150	80.03		
76	Carvedilol 25mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	2 026 174		1 215 704	60.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Rubitrend 25	R15.30	Pack of 28 tablets	14	100	84.97	222001085	CO
						810 470	40.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	Carloc 25	R15.53	Pack of 30 tablets	14	100	83.54		
77	Carvedilol 6,25mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	1 516 859		910 115	60.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Rubitrend 25	R5.73	Pack of 28 tablets	14	200	90.00	222001086	CO
						606 744	40.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	Carloc 6,25	R5.75	Pack of 30 tablets	14	240	89.69		
78	Cetirizine 10mg tablet; 28/30 tablets	Class 19	Pack of 28/30 tablets	8 156 396	8 976 987	3 226 939	35.95%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Cetirizine 10 mg	R4.00	Pack of 28 tablets	14	10	90.00	222000438	CO
						3 160 249	35.20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Cetirizine 10 Unimed	R4.36	Pack of 28 tablets	14	100	88.14		
						2 589 798	28.85%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF CETIRIZINE 10	R4.79	Pack of 28 tablets	14	100	72.23		
87	Citalopram 20mg tablet; 28/30 tablets	Class 26	Pack of 28/30 tablets	2 886 363		1 731 818	60.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF CITALOPRAM 20	R6.88	Pack of 28 tablets	14	100	82.79	180129661	CO
88	Clonazepam 0,5mg tablet; 84/90 tablets		Pack of 84/90 tablets	292 119		292 119	100.00%	Pharmacare Distribution (Pty) Ltd	MAAA0044115	VBVW1	Rivotril 0.5mg	R213.12	Pack of 100 tablets	14	1	90.00	189710177	CO
	Product Awarded: Clonazepam 0,5mg tablet; 100 tablets																	
92	Clopidogrel 75mg tablet; 28/30 tablets		Pack of 28/30 tablets	317 201		317 201	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Beclop	R18.77	Pack of 30 tablets	14	200 x 30s	97.60	181860507	CO
93	Clozapine 25mg tablet; 100 tablets		Pack of 100 tablets	144 584		144 584	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Clozapine 25 Oethmaan	R27.37	Pack of 100 tablets	14	20	96.20	189710069	CO
94	Clozapine 100mg tablet; 100 tablets		Pack of 100 tablets	283 842		283 842	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Clozapine 100 Oethmaan	R82.80	Pack of 100 tablets	14	20	96.20	189710025	CO
95	Colchicine 0.5mg tablet; 12 tablets		Pack of 12 tablets	643 170		643 170	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	CINITEO 0,5 mg	R12.99	Pack of 12 tablets	14	10 pack	90.00	181937413	CO
96	Deferasirox 180mg film-coated tablet; 30 tablets		Pack of 30 tablets	4 265		4 265	100.00%	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Jadenu 180mg	R1 574.44	Pack of 30 tablets	14	1	90.00	222001427	CO
97	Deferasirox 250mg tablet; 28/30 tablets		Pack of 28/30 tablets	3 901		3 901	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Deferasirox 250 Alkem	R499.00	Pack of 30 tablets (3 x 10)	14	1	90.00	222001848	CO
98	Deferasirox 500mg tablet; 28/30 tablets		Pack of 28/30 tablets	6 256		6 256	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Deferasirox 500 Alkem	R747.00	Pack of 30 tablets (3 x 10)	14	1	90.00	222001849	CO
99	Desmopressin 0,1mg tablet; 30 tablets		Pack of 30 tablets	21 386		21 386	100.00%	Ferring (Pty) Ltd	MAAA0005879	VXY92	DDAVP 0,1mg TABLETS 30'S	R441.41	Pack of 30 tablets	14	5	90.00	180772047	CO
100	Desmopressin 0,2mg tablet; 30 tablets		Pack of 30 tablets	19 740		19 740	100.00%	Ferring (Pty) Ltd	MAAA0005879	VXY92	DDAVP 0,2mg TABLETS 30'S	R611.62	Pack of 30 tablets	14	5	90.00	181795796	CO
101	Desmopressin 120mcg melt tablet; 30 tablets		Pack of 30 tablets	1 478		1 478	100.00%	Ferring (Pty) Ltd	MAAA0005879	VXY92	MINIRIN MELT 120mcg 30's	R611.62	Pack of 30 tablets	14	5	90.00	222001428	CO
102	Desmopressin 240mcg melt tablet; 30 tablets		Pack of 30 tablets	710		710	100.00%	Ferring (Pty) Ltd	MAAA0005879	VXY92	MINIRIN MELT 240mcg 30's	R1 224.00	Pack of 30 tablets	14	5	90.00	222001429	CO
105	Diazepam 5mg tablet; 14 tablets		Pack of 14 tablets	169 336		169 336	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	DOVAL 5mg Tablets	R7.43	Pack of 14 tablets	14	50 x 14 tablets	92.27	222001090	CO

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
107	Diclofenac 50mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 880 627		1 880 627	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Diclofenac 50 Oethmaan	R5.96	Pack of 28 tablets	14	264	96.20	222001430	CO
108	Diclofenac 50mg tablet; 9 tablets		Pack of 9 tablets	127 000		127 000	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Diclofenac 50 Oethmaan	R2.85	Pack of 9 tablets	14	264	95.56	222001431	CO
111	Doxazosin 1mg tablet; 30 tablets	Class 7	Pack of 30 tablets	515 846		515 846	100.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	CARDUGEN 1 MG	R17.99	Pack of 30 tablets	14	50	90.00	189763011	CO
112	Doxazosin 4mg tablet; 30 tablets	Class 6	Pack of 30 tablets	5 391 648		4 313 318	80.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	URODOXA 4 mg	R14.21	Pack of 30 tablets	14	5 pack	90.00	189763013	CO
						1 078 330	20.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	CARDUGEN 4 MG	R16.09	Pack of 30 tablets	14	50	78.09		
113	Doxazosin 4mg tablet; 30 tablets	Class 8	Pack of 30 tablets	1 626 402		1 626 402	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	URODOXA 4 mg	R14.21	Pack of 30 tablets	14	5 pack	90.00	189763013	CO
114	Enalapril 10mg tablet; 28/30 tablets	Class 3	Pack of 28/30 tablets	73 089 993		19 766 153	27.04%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Enalapril 10 Unimed	R3.82	Pack of 28 tablets	14	200	96.24	189708531	CO
						18 242 204	24.96%	Pharmacare Limited	MAAA0008452	V2205	PHARMAPRESS 10MG 28'S B/P - TENDER	R3.87	Pack of 28 tablets	14	220	88.82		
						17 757 498	24.30%	Smart Pharmaceuticals (Pty) Ltd	MAAA1003704	V2CW0	NATRAPRESS 10 mg	R4.31	Pack of 28 tablets	14	288	86.46		
						17 324 138	23.70%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	Tenezil 10	R4.06	Pack of 28 tablets	14	288	84.35		
115	Enalapril 20mg tablet; 28/30 tablets	Class 4	Pack of 28/30 tablets	13 964 603		5 026 756	36.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Enalapril 20 Unimed	R5.28	Pack of 28 tablets	14	200	96.24	189710187	CO
						4 619 873	33.08%	Smart Pharmaceuticals (Pty) Ltd	MAAA1003704	V2CW0	NATRAPRESS 20 mg	R5.84	Pack of 28 tablets	14	288	88.45		
						4 317 975	30.92%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	Tenezil 20	R5.71	Pack of 28 tablets	14	288	82.67		
116	Enalapril 5mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	11 173 764		3 992 882	35.73%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Enalapril 5 Unimed	R3.50	Pack of 28 tablets	14	200	96.24	189710188	CO
						3 605 792	32.27%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Enalapril 5 mg	R3.62	Pack of 28 tablets	14	10	86.91		
						3 575 090	32.00%	Smart Pharmaceuticals (Pty) Ltd	MAAA1003704	V2CW0	NATRAPRESS 5 mg	R3.96	Pack of 28 tablets	14	200	86.17		
118	Escitalopram 5mg tablet; 30 tablets	Class 25	Pack of 30 tablets	91 638		91 638	100.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	LEXAMIL 5	R10.35	Pack of 30 tablets	14	20	90.00	222001850	CO
120	Ezetimibe 10mg tablet; 30 tablets		Pack of 30 tablets	65 440		65 440	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	EZOTAK	R28.03	Pack of 30 tablets	14	3 pack	90.00	181797762	CO
124	Ferrous salt, providing 50 to 65mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	19 851 724		19 851 724	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FERROUS SULPHATE COMPOUND TABLETS	R8.29	Pack of 28 tablets	14	300	90.00	181923348	CO
125	Ferrous salt, providing 50 to 65mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule; 56/60 tablets/capsules		Pack of 56/60 tablets/capsules	2 354 221		2 354 221	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FERROUS SULPHATE COMPOUND TABLETS	R15.21	Pack of 56 tablets	14	300	90.00	181923349	CO
126	Ferrous salt, providing 50 to 65mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule; 84/90 tablets/capsules		Pack of 84/90 tablets/capsules	1 715 404		1 715 404	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FERROUS SULPHATE COMPOUND TABLETS	R22.20	Pack of 84 tablets	14	250	90.00	181923350	CO
128	Fludrocortisone 0,1mg tablet; 100 tablets		Pack of 100 tablets	2 282		2 282	100.00%	Pharmacare Limited	MAAA0008452	V2205	FLORINEF TAB 0.1MG 100 BTL ZA	R355.98	Pack of 100 tablets	14	10	90.00	189710316	CO
130	Fluoxetine 20mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	3 044 719		1 826 831	60.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Fluoxetine 20 Oethmaan	R6.59	Pack of 28 capsules	14	10	96.20	189712353	CO
						1 217 888	40.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Fluoxetine 20 Unimed	R6.68	Pack of 30 capsules	14	75	95.01		
131	Fluoxetine 20mg tablets/capsules; 100 tablets/capsules		Pack of 100 tablets/capsules	222 187		222 187	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Fluoxetine 20 Oethmaan	R21.47	Pack of 100 capsules	14	100	96.20	180106075	CO
132	Folic acid 5mg tablet; 100 tablets		Pack of 100 tablets	312 536		312 536	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FOLIC ACID 5	R12.63	Pack of 100 tablets	14	126	90.00	189757933	CO
133	Folic acid 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	29 849 781		29 849 781	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FOLIC ACID 5	R5.73	Pack of 28 tablets	14	300	90.00	189713751	CO
134	Furosemide 40mg tablet; 112/120 tablets		Pack of 112/120 tablets	400 677		400 677	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	DIURESIX TABLETS	R13.52	Pack of 112 tablets	14	50 x 112 tablets	92.27	181859966	PG
135	Furosemide 40mg tablet; 28/30 tablets		Pack of 28/30 tablets	10 737 191		3 609 140	33.61%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	DIURESIX TABLETS	R4.08	Pack of 28 tablets	14	200	91.60	180339712	PG
						3 581 953	33.36%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Furosemide 40 Unimed	R4.29	Pack of 28 tablets	14	200	90.91		
						3 546 098	33.03%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	DEFULIDE 40	R4.05	Pack of 28 tablets	14	200	90.00		
136	Furosemide 40mg tablet; 56/60 tablets		Pack of 56/60 tablets	3 991 851		2 395 111	60.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	DIURESIX TABLETS	R7.19	Pack of 56 tablets	14	200	91.64	181798154	PG
						1 596 740	40.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Furosemide 40 Unimed	R7.61	Pack of 56 tablets	14	200	90.32		
137	Furosemide 40mg tablet; 84/90 tablets		Pack of 84/90 tablets	880 750		880 750	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	DIURESIX TABLETS	R10.81	Pack of 84 tablets	14	50 x 84 tablet	91.60	181798156	PG
138	Furosemide 500mg tablet; 100 tablets		Pack of 100 tablets	11 872		11 872	100.00%	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	LASIX 500MG TABS 100'S	R3 047.50	Pack of 100 tablets	14	1	90.00	189710019	CO
139	Gabapentin 100mg capsule; 100 capsules		Pack of 100 capsules	52 607		52 607	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Gabapentin 100 MSQ	R41.86	Pack of 100 capsules	14	10 x 100s	91.00	180103509	CO
140	Gabapentin 300mg capsule; 100 capsules		Pack of 100 capsules	30 487		30 487	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Gabapentin 300 MSQ	R85.30	Pack of 100 capsules	14	10 x 100s	92.82	180103511	CO
141	Gabapentin 400mg capsule; 100 capsules		Pack of 100 capsules	2 897		2 897	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Levoneptin 400	R99.00	Pack of 100 capsules (10 x 10)	14	1	90.00	180103512	CO

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
143	Glibenclamide 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 913 414		1 913 414	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glibenclamide 5 Oethmaan	R3.37	Pack of 28 tablets	14	300	96.20	180189209	PG
144	Glibenclamide 5mg tablet; 56/60 tablets		Pack of 56/60 tablets	913 563		913 563	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glibenclamide 5 Oethmaan	R5.28	Pack of 56 tablets	14	200	96.20	180340162	PG
145	Glibenclamide 5mg tablet; 84/90 tablets		Pack of 84/90 tablets	298 558		298 558	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glibenclamide 5 Oethmaan	R6.22	Pack of 84 tablets	14	100	96.20	180340166	PG
147	Glimepiride 1mg tablet; 28/30 tablets		Pack of 28/30 tablets	3 051 847		1 831 108	60.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glimepiride 1 Oethmaan	R2.94	Pack of 28 tablets	14	100	90.68	222001094	CO
						1 220 739	40.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Glimepiride 1 mg	R2.77	Pack of 28 tablets	14	10	90.00		
148	Glimepiride 2mg tablet; 28/30 tablets		Pack of 28/30 tablets	6 516 102		2 262 829	34.73%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glimepiride 2 Oethmaan	R4.15	Pack of 28 tablets	14	100	96.20	222001095	CO
						2 217 902	34.04%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Glimepiride 2 Unimed	R4.24	Pack of 28 tablets	14	200	94.29		
						2 035 370	31.24%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Glimepiride 2 mg	R4.31	Pack of 28 tablets	14	10	86.53		
149	Glimepiride 4mg tablet; 28/30 tablets		Pack of 28/30 tablets	5 964 730		3 578 838	60.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glimepiride 4 Oethmaan	R6.10	Pack of 28 tablets	14	100	96.20	222001096	CO
149						2 385 892	40.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Glimepiride 4 Unimed	R6.24	Pack of 28 tablets	14	200	94.17		
151	Haloperidol 1,5mg tablet; 100 tablets		Pack of 100 tablets	328 220		328 220	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 1,5 Oethmaan	R17.18	Pack of 100 tablets	14	50	96.20	189710367	CO
152	Haloperidol 5mg tablet; 100 tablets		Pack of 100 tablets	165 858		165 858	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 5 Oethmaan	R17.25	Pack of 100 tablets	14	50	96.20	189710327	CO
153	Haloperidol 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 889 860		1 889 860	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 5 Oethmaan	R4.49	Pack of 28 tablets	14	100	96.20	181923352	CO
154	Haloperidol 5mg tablet; 56/60 tablets		Pack of 56/60 tablets	328 700		328 700	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 5 Oethmaan	R10.29	Pack of 56 tablets	14	50	96.20	181923353	CO
155	Hydralazine 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	1 520 546		1 520 546	100.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Hydralazine HCL 25 Kiara	R25.49	Pack of 56 tablets	14	100	90.00	181798157	PG
156	Hydralazine 25mg tablet; 84/90 tablets		Pack of 84/90 tablets	458 220		458 220	100.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Hydralazine HCL 25 Kiara	R40.16	Pack of 84 tablets	14	100	81.78	180091224	PK
157	Hydrochlorothiazide 12,5mg tablet; 28/30 tablets	Class 32	Pack of 28/30 tablets	91 555 768		54 933 461	60.00%	Pharmacare Limited	MAAA0008452	V2205	RIDAQ TABS 12.5MG 28'S	R4.04	Pack of 28 tablets	14	250	90.00	181821883	PG
						36 622 307	40.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Zidaflo 12,5	R4.13	Pack of 28 tablets	14	10	88.00		
158	Hydrochlorothiazide 25mg tablet; 28/30 tablets	Class 33	Pack of 28/30 tablets	29 178 858		8 326 681	28.54%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unizide 25 mg	R3.85	Pack of 28 tablets	14	200	96.24	180190405	PG
						7 463 212	25.58%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF HYDROCHLOROTHIAZIDE 25	R4.01	Pack of 28 tablets	14	300	86.26		
						7 038 399	24.12%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Zidaflo 25	R4.22	Pack of 28 tablets	14	10	81.35		
						6 350 565	21.76%	Pharmacare Limited	MAAA0008452	V2205	RIDAQ TABS 25MG 28'S BB - TENDER	R4.56	Pack of 28 tablets	14	200	73.40		
160	Hyoscine butylbromide 10mg tablet; 10 tablets		Pack of 10 tablets	7 958 319		7 958 319	100.00%	Pharmacare Limited	MAAA0008452	V2205	HYOSPASMOL TABS 10MG 10'S BB - TENDER NEW	R24.89	Pack of 10 tablets	14	40	90.00	189711820	CO
161	Ibuprofen 200mg tablet; 15 tablets		Pack of 15 tablets	33 855 762		13 242 343	39.11%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 200	R3.07	Pack of 15 tablets	14	300	96.24	180339460	PG
						11 093 077	32.77%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austifen 200 mg 15's	R3.39	Pack of 15 tablets	14	10	80.62		
						9 520 342	28.12%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	IBUNATE 200mg	R3.78	Pack of 15 tablets	14	300	69.19		
162	Ibuprofen 200mg tablet; 42 tablets		Pack of 42 tablets	3 691 336		3 691 336	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 200	R7.08	Pack of 42 tablets	14	200	96.24	181798173	PG
163	Ibuprofen 200mg tablet; 84/90 tablets		Pack of 84/90 tablets	1 301 908		1 301 908	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 200	R12.63	Pack of 84 tablets	14	200	96.24	180339461	PG
164	Ibuprofen 400mg tablet; 15 tablets		Pack of 15 tablets	10 806 591		8 645 273	80.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 400	R4.13	Pack of 15 tablets	14	200	96.24	181923355	CO
						2 161 318	20.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austifen 400 mg 15's	R4.45	Pack of 15 tablets	14	10	83.03		
165	Ibuprofen 400mg tablet; 84/90 tablets		Pack of 84/90 tablets	1 789 567		1 789 567	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 400	R20.00	Pack of 84 tablets	14	100	96.24	189711816	CO
168	Indomethacin 25mg capsule; 100 capsules		Pack of 100 capsules	1 336 757		1 336 757	100.00%	Resmed Healthcare CC	MAAA0010098	VCEJ2	Acuflex	R17.50	Pack of 100 capsules	14	100	96.67	189714494	CO
169	Isosorbide dinitrate 10mg tablet; 84/90 tablets		Pack of 84/90 tablets	616 217		616 217	100.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Isosorbide dinitrate 10 Kiara	R20.99	Pack of 84 tablets	14	100	90.00	180146434	CO
170	Isosorbide dinitrate 5mg sublingual tablet; 50 tablets	Class 16	Pack of 50 tablets	800 361		800 361	100.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Isosorbide dinitrate 5 Kiara	R18.98	Pack of 50 tablets	14	50	90.00	189710453	CO
171	Isosorbide mononitrate 20mg; 56/60 tablets		Pack of 56/60 tablets	166 975		166 975	100.00%	Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	Ismo 20mg 56's	R180.00	Pack of 56 tablets	14	1	90.00	181773023	CO
172	Isotretinoin 10mg capsule; 60 capsules		Pack of 60 capsules	10 673		10 673	100.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	ACNETRET 10	R156.16	Pack of 60 capsules	14	10	90.00	189712676	CO
173	Isotretinoin 20mg capsules; 60 capsules		Pack of 60 capsules	18 388		1 839	10.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	ACNETRET 20	R215.87	Pack of 60 capsules (1 x 2 packs of 60 capsules)	14	10	90.00	189712688	CO
						16 549	90.00%	Acino Pharma (Pty) Ltd	MAAA0009244	VGS73	ORATANE 20mg	R285.78	Pack of 60 capsules	14	5	60.85		
174	Lamotrigine 100mg tablet; 56/60 tablets		Pack of 56/60 tablets	616 430		616 430	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Lamotrigine 100 Unimed	R25.16	Pack of 56 tablets	14	50	91.26	222001417	CO
175	Lamotrigine 200mg tablet; 56/60 tablets		Pack of 56/60 tablets	86 100		86 100	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Lamotrigine 200 Unimed	R48.36	Pack of 56 tablets	14	25	91.64	222001418	CO
176	Lamotrigine 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	506 706		506 706	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Lamotrigine 25 Unimed	R12.59	Pack of 56 tablets	14	50	90.21	222001419	CO
177	Lamotrigine 50mg tablet; 56/60 tablets		Pack of 56/60 tablets	580 913		580 913	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Lamotrigine 50 MSQ	R15.11	Pack of 60 tablets	14	50 x 60s	97.60	180108137	CO

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
182	Leflunomide 10mg tablet; 30 tablets		Pack of 30 tablets	7 076		7 076	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	ARTHROD 10 mg	R66.68	Pack of 30 tablets	14	3 pack	90.00	181781164	CO
183	Leflunomide 20mg tablet; 30 tablets		Pack of 30 tablets	90 405		90 405	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	ARTHROD 20 mg	R87.35	Pack of 30 tablets	14	3 pack	90.00	181753191	CO
184	Levetiracetam 250mg tablets; 30 tablets		Pack of 30 tablets	248 683		248 683	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Levetiracetam 250 Hetero	R17.96	Pack of 30 tablets	14	60	90.00	181934912	CO
185	Levetiracetam 500mg tablets; 30 tablets		Pack of 30 tablets	220 410		220 410	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Levetiracetam 500 Hetero	R28.98	Pack of 30 tablets	14	60	90.00	222001100	CO
186	Levetiracetam 750mg tablets; 30 tablets		Pack of 30 tablets	138 424		138 424	100.00%	Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Redilev 750	R69.00	Pack of 30 tablets	14	1	90.00	181934915	CO
187	Levothyroxine sodium 0,025mg tablet; 28/30 tablets		Pack of 28/30 tablets	98 972		98 972	100.00%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	Roidace 25	R5.84	Pack of 30 tablets	14	240	90.00	222001581	CO
188	Levothyroxine sodium 0,05mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 377 123		1 377 123	100.00%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	Roidace 50	R5.84	Pack of 30 tablets	14	240	90.00	222001582	CO
189	Levothyroxine sodium 0,1mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 436 059		1 436 059	100.00%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	Roidace 100	R6.57	Pack of 30 tablets	14	240	90.00	222001583	CO
192	Lithium 250mg tablet; 100 tablets		Pack of 100 tablets	141 938		141 938	100.00%	Pharmacare Limited	MAAA0008452	V2205	CAMCOLIT 250MG TAB SEC 100	R404.86	Pack of 100 tablets	14	5	90.00	189710365	CO
193	Lithium 400mg tablet; 100 tablets		Pack of 100 tablets	30 620		30 620	100.00%	Pharmacare Limited	MAAA0008452	V2205	CAMCOLIT 400MG TAB SEC 100	R432.64	Pack of 100 tablets	14	5	90.00	189710053	CO
194	Loperamide 2mg tablet; 6 tablets		Pack of 6 tablets	8 245 225		8 245 225	100.00%	Pharmacare Limited	MAAA0008452	V2205	GASTRON 2MG TABS 6'S	R1.88	Pack of 6 tablets	14	200	90.00	189710479	CO
196	Lorazepam 2,5mg tablet; 100 tablets		Pack of 100 tablets	34 449		34 449	100.00%	Pharmacare Limited	MAAA0008452	V2205	TRANQIPAM 2.5MG TABS 100'S	R166.14	Pack of 100 tablets	14	10	90.00	189714603	CO
197	Losartan 100mg tablet; 28/30 tablets	Class 18	Pack of 28/30 tablets	1 066 559		1 066 559	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Losartan 100 Unimed	R12.49	Pack of 28 tablets	14	50	96.24	181936085	CO
198	Losartan 50mg tablet; 28/30 tablets	Class 17	Pack of 28/30 tablets	1 816 805		1 816 805	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Losartan 50 Unimed	R7.12	Pack of 28 tablets	14	50	96.24	181936086	CO
199	Mesalazine 400mg tablet; 90 tablets		Pack of 90 tablets	33 633		33 633	100.00%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Asacol Tablets 400mg	R384.63	Pack of 90 tablets	14	20	90.00	189762990	CO
200	Metformin 500mg tablet; 112/120 tablets		Pack of 112/120 tablets	1 010 500		1 010 500	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	VATAMET 500	R17.83	Pack of 112 tablets	14	25	88.97	222001105	CO
201	Metformin 500mg tablet; 56/60 tablets		Pack of 56/60 tablets	16 521 439		6 154 770	37.25%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-500	R8.61	Pack of 56 tablets	14	144	96.24	180670492	PG
						5 733 964	34.71%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	VATAMET 500	R8.86	Pack of 56 tablets	14	100	89.66		
						4 632 705	28.04%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metformin 500 mg 56's	R10.29	Pack of 56 tablets	14	10	72.44		
202	Metformin 500mg tablet; 84/90 tablets		Pack of 84/90 tablets	4 996 135		2 997 681	60.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-500	R12.58	Pack of 84 tablets	14	112	95.81	180339480	PG
						1 998 454	40.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	VATAMET 500	R12.52	Pack of 84 tablets	14	75	92.27		
203	Metformin 850mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 222 614		1 222 614	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	VATAMET 850	R7.13	Pack of 28 tablets	14	50	89.14	189711806	CO
204	Metformin 850mg tablet; 56/60 tablets		Pack of 56/60 tablets	10 347 954		3 572 918	34.53%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-850	R12.06	Pack of 56 tablets	14	112	95.49	180670494	PG
						3 452 436	33.36%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	VATAMET 850	R11.96	Pack of 56 tablets	14	50	92.27		
						3 322 600	32.11%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	ROMIDAB 850 mg TABLETS	R12.12	Pack of 56 tablets	14	10 pack	88.80		
205	Metformin 850mg tablet; 84/90 tablets		Pack of 84/90 tablets	4 910 579		2 946 347	60.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-850	R17.41	Pack of 84 tablets	14	96	96.24	189711808	CO
						1 964 232	40.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	VATAMET 850	R17.46	Pack of 84 tablets	14	50	92.01		
206	Methyldopa 250mg tablet; 56/60 tablets		Pack of 56/60 tablets	1 174 054		1 174 054	100.00%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	TIMUCEN 250	R42.20	Pack of 56 tablets	14	150	90.00	189711810	CO
207	Methyldopa 250mg tablet; 84/90 tablets		Pack of 84/90 tablets	1 051 497		1 051 497	100.00%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	TIMUCEN 250	R59.98	Pack of 84 tablets	14	150	90.00	189710812	CO
208	Methylphenidate 10mg tablet; 30 tablets		Pack of 30 tablets	1 652 873		1 652 873	100.00%	Acino Pharma (Pty) Ltd	MAAA0009244	VGS73	METHYLPHENIDATE HCL 10MG	R79.35	Pack of 30 tablets	14	10	90.00	189710452	CO
209	Methylphenidate 18 - 20mg modified release tablet/capsule; 30 tablets/capsules		Pack of 30 tablets/capsules	230 000		230 000	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	ACERTA 18	R114.61	Pack of 30 tablets	14	16	90.00	222001106	CO
210	Methylphenidate 27 - 30mg modified release tablet/capsule; 30 tablets/capsules		Pack of 30 tablets/capsules	106 888		106 888	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	ACERTA 27	R143.26	Pack of 30 tablets	14	12	90.00	222001107	CO
211	Methylphenidate 36 - 40mg modified release tablet/capsule; 30 tablets/capsules		Pack of 30 tablets/capsules	23 279		23 279	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	ACERTA 36	R152.81	Pack of 30 tablets	14	12	90.00	222001108	CO
212	Metoclopramide 10mg tablet; 10 tablets		Pack of 10 tablets	5 747 273		4 597 818	80.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metoclopramide 10mg	R1.89	Pack of 10 tablets	14	10	90.00	181798176	PG
						1 149 455	20.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Metoclopramide 10 Oethmaan	R2.35	Pack of 10 tablets	14	200	74.30		
213	Metoclopramide 10mg tablet; 100 tablets		Pack of 100 tablets	72 100		72 100	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Metoclopramide 10 Oethmaan	R14.13	Pack of 100 tablets	14	100	96.20	189711057	CO
216	Midazolam 15mg tablet; 20 tablets		Pack of 20 tablets	2 120		2 120	100.00%	Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	Dormicum Tabs 15mg 20's	R160.00	Pack of 20 tablets	14	1	90.00	180190409	CO
217	Midazolam 7,5mg tablet; 20 tablets		Pack of 20 tablets	1 854		1 854	100.00%	Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	Dormicum Tabs 7.5mg 20's	R111.00	Pack of 20 tablets	14	1	90.00	181751133	CO
218	Minoxidil 10mg tablet; 100 tablets		Pack of 100 tablets	4 996		4 996	100.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Loniten 10mg TAB, 100s	R786.04	Pack of 100 tablets	14	1	90.00	189714351	CO
219	Minoxidil 5mg tablet; 100 tablets		Pack of 100 tablets	5 610		5 610	100.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Loniten 5mg TAB, 100s	R449.22	Pack of 100 tablets	14	1	90.00	189714350	CO
220	Montelukast 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	70 622		70 622	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Montrahet 10mg	R13.52	Pack of 30 tablets	14	10	90.00	222001109	CO
221	Montelukast 4mg chewable tablet; 28/30 tablets		Pack of 28/30 tablets	8 036		8 036	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Montrahet 4mg	R9.49	Pack of 30 tablets	14	10	90.00	222001110	CO
222	Montelukast 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	60 400		60 400	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Montrahet 5mg	R11.15	Pack of 30 tablets	14	210	90.00	222001111	CO

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
223	Morphine 10mg modified release tablet; 60 tablets		Pack of 60 tablets	44 703		44 703	100.00%	Mundipharma (Pty) Ltd	MAAA0228483	V32G6	MST Continus	R427.38	Pack of 60 tablets	7	12 x 60's	90.00	222001112	CO
224	Morphine 30mg modified release tablet; 60 tablets		Pack of 60 tablets	40 000		40 000	100.00%	Mundipharma (Pty) Ltd	MAAA0228483	V32G6	MST Continus	R779.50	Pack of 60 tablets	7	12 x 60's	90.00	222001113	CO
225	Morphine 60mg modified release tablet; 60 tablets		Pack of 60 tablets	2 060		2 060	100.00%	Mundipharma (Pty) Ltd	MAAA0228483	V32G6	MST Continus	R1 139.03	Pack of 60 tablets	7	6 x 60's	90.00	222001114	CO
226	Nicotinamide 100mg tablet; 28/30 tablets		Pack of 28/30 tablets	352 958		352 958	100.00%	Portfolio Pharmaceuticals (Pty) Ltd	MAAA0039590	VWB81	Portfolio Nicotinamide 100mg	R7.20	Pack of 28 tablets	14	500	86.90	180339515	PG
227	Nicotinamide 100mg tablet; 84/90 tablets		Pack of 84/90 tablets	14 220		14 220	100.00%	Portfolio Pharmaceuticals (Pty) Ltd	MAAA0039590	VWB81	Portfolio Nicotinamide 100mg	R16.50	Pack of 84 tablets	14	50	90.00	181917398	CO
232	Nimodipine 30mg tablet; 100 tablets		Pack of 100 tablets	4 486		4 486	100.00%	Bayer (Pty) Ltd	MAAA0009623	V6390	Nimotop 30mg	R1 207.42	Pack of 100 tablets	14	1 x 100	90.00	189763128	CO
233	Olanzapine 2,5mg tablet; 28/30 tablets		Pack of 28/30 tablets	145 644		145 644	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Olanzapine 2.5 MSQ	R8.65	Pack of 30 tablets	14	100 x 30s	93.01	222001115	CO
234	Olanzapine 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	596 254		596 254	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Meltolan 5	R9.40	Pack of 30 tablets (3 x 10)	14	1	90.00	181936077	CO
235	Olanzapine 5mg Oral Dispersible Tablet; 28/30 tablets		Pack of 28/30 tablets	21 606		21 606	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	ONZIR 5	R17.36	Pack of 30 tablets	14	5 pack	90.00	222001562	CO
236	Olanzapine 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	840 182		840 182	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	FLOITRA 10 mg	R13.36	Pack of 30 tablets	14	3 pack	90.00	181936076	CO
237	Olanzapine 10mg Oral Dispersible Tablet; 28/30 tablets		Pack of 28/30 tablets	43 965		43 965	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	ONZIR 10 mg	R24.86	Pack of 30 tablets	14	3 pack	90.00	222001563	CO
238	Omeprazole 10mg dispersible tablet; 28/30 tablets		Pack of 28/30 tablets	378 210		378 210	100.00%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Losec Mups 10mg	R55.66	Pack of 28 tablets	14	48	90.00	181868887	CO
239	Omeprazole 10mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]	Class 11 Series 1	Pack of 28/30 tablets/capsules	6 551 839		5 896 655	90.00%	Activo Health (Pty) Ltd	MAAA0391119	V32D3	Corpocid 10	R9.89	Pack of 30 capsules	14	50	80.10	181936078	CO
240	Omeprazole 20mg tablet/capsule; 14 tablets/capsules [Items 239 + 240 + 241 will be considered a series]	Class 12 Series 1	Pack of 14 tablets/capsules	8 954 312		8 058 881	90.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Omexor	R5.65	Pack of 14 capsules	14	75	96.24	189762924	CO
						895 431	10.00%	Activo Health (Pty) Ltd	MAAA0391119	V32D3	Corpocid 20	R6.82	Pack of 14 capsules	14	50	71.36		
241	Omeprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]	Class 10 Series 1	Pack of 28/30 tablets/capsules	9 307 294		8 376 565	90.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Omexor	R8.27	Pack of 28 capsules	14	75	96.24	189762923	CO
						930 729	10.00%	Activo Health (Pty) Ltd	MAAA0391119	V32D3	Corpocid 20	R9.89	Pack of 30 capsules	14	50	72.37		
242	Orphenadrine 50mg tablet; 28/30 tablets		Pack of 28/30 tablets	4 377 904		4 377 904	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	DISIPAL	R18.98	Pack of 28 tablets	14	50	90.00	180339583	PG
243	Orphenadrine 50mg tablet; 56/60 tablets		Pack of 56/60 tablets	1 897 848		1 897 848	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	DISIPAL	R36.23	Pack of 56 tablets	14	50	90.00	180339585	PG
244	Orphenadrine 50mg tablet; 84/90 tablets		Pack of 84/90 tablets	382 532		382 532	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	DISIPAL	R50.00	Pack of 84 tablets	14	50	90.00	180339586	PG
245	Oxazepam 10mg tablet; 100 tablets		Pack of 100 tablets	52 568		52 568	100.00%	Pharmacare Limited	MAAA0008452	V2205	PURATA TABS 10MG 100'S	R60.40	Pack of 100 tablets	14	20	90.00	189712225	CO
247	Oxazepam 30mg tablet; 100 tablets		Pack of 100 tablets	24 426		24 426	100.00%	Arya Pharma (Pty) Ltd	MAAA0717051	VF6A8	ZIMTEC 30	R35.06	Pack of 100 tablets	14	20	90.00	189714612	CO
248	Oxybutynin 5mg tablet; 84/90 tablets		Pack of 84/90 tablets	347 883		347 883	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Oxybutynin 5 Oethmaan	R33.24	Pack of 84 tablets	14	5	96.20	222001116	CO
249	Pancreatin 150mg equivalent to Amylase 8000 FIP units, Lipase 10000 FIP units and Protease 600 FIP units per capsule; 100 capsules		Pack of 100 capsules	27 429		27 429	100.00%	Abbott Laboratories SA (Pty) Ltd	MAAA0030395	V2150	Creon 10000	R731.50	Pack of 100 capsules	14	3	90.00	181747895	CO
250	Pancreatin 300mg equivalent to Amylase 18 000 FIP units, Lipase 25000 FIP units and Protease 1000 FIP units per capsule; 100 capsules		Pack of 100 capsules	36 004		36 004	100.00%	Abbott Laboratories SA (Pty) Ltd	MAAA0030395	V2150	Creon 25000	R1 486.80	Pack of 100 capsules	14	3	90.00	180231590	CO
254	Paracetamol 500mg tablet; 100 tablets		Pack of 100 tablets	11 974 876		4 153 465	34.68%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Zypol	R13.06	Pack of 100 tablets	14	100	96.24	189753434	CO
						3 913 942	32.68%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Painogestic Tablets	R13.29	Pack of 100 tablets	14	74 x 100	90.69		
						3 907 468	32.63%	Resmed Healthcare CC	MAAA0010098	VCEJ2	Cetapon	R13.95	Pack of 100 tablets	14	100	90.54		
255	Paracetamol 500mg tablet; 20 tablets		Pack of 20 tablets	126 742 213		34 220 398	27.00%	Resmed Healthcare CC	MAAA0010098	VCEJ2	Cetapon	R2.99	Pack of 20 tablets	14	500	96.67	180155484	PG
						27 883 287	22.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Donapan 500 Tablets	R3.30	Pack of 20 tablets	14	216	86.87		
						32 952 975	26.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Zypol	R3.34	Pack of 20 tablets	14	300	85.70		
						31 685 553	25.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Paracetamol 500 mg	R3.16	Pack of 20 tablets	14	10	84.88		
261	Phenytoin 100mg capsule/tablet; 100 tablets/capsules		Pack of 100 tablets/capsules	280 675		280 675	100.00%	Pharmacare Limited	MAAA0008452	V2205	PHENYTOIN CAPSULES 100MG 100'S	R71.90	Pack of 100 capsules	14	15	90.00	189715312	CO
262	Phenytoin 100mg capsule/tablet; 84/90 tablets/capsules		Pack of 84/90 tablets/capsules	1 657 481		1 657 481	100.00%	Pharmacare Limited	MAAA0008452	V2205	PHENYTOIN SODIUM TAB 100MG 84'S BB - STATE ONLY	R51.64	Pack of 84 tablets	14	20	90.00	180342249	PG
263	Potassium chloride 600mg tablet; 100 tablets		Pack of 100 tablets	394 586		394 586	100.00%	Pharmacare Limited	MAAA0008452	V2205	PLENISH-K 600MG TABS 100'S	R66.47	Pack of 100 tablets	14	15	90.00	181917399	CO
264	Pramipexole 0,25mg tablet; 100 tablets	Class 24	Pack of 100 tablets	21 475		21 475	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	OXPOLA 0,25mg	R132.25	Pack of 100 tablets	14	10	90.00	181758021	CO
268	Prednisone 5mg tablet; 100 tablets		Pack of 100 tablets	571 948		571 948	100.00%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	Be-Tabs Prednisone 5 mg	R14.49	Pack of 100 tablets	14	50	90.00	189714134	CO
269	Prednisone 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	10 799 500		7 559 650	70.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	TROLIC	R5.17	Pack of 28 tablets	14	100	90.00	181798179	CO
						3 239 850	30.00%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	Be-Tabs Prednisone 5 mg	R5.66	Pack of 28 tablets	14	100	81.47		
270	Prednisone 5mg tablet; 56/60 tablets		Pack of 56/60 tablets	1 505 388		1 505 388	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	TROLIC	R10.78	Pack of 56 tablets	14	100	90.00	181860002	PG
271	Pregabalin 150mg capsule; 56/60 capsules		Pack of 56/60 capsules	57 602		57 602	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Regakem 150 mg	R38.27	Pack of 56 capsules (8 x 7)	14	1	90.00	181836131	CO
272	Pregabalin 25mg capsule; 56/60 capsules		Pack of 56/60 capsules	81 376		81 376	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	NERGIL 25 mg	R20.51	Pack of 60 capsules	14	3 pack	90.00	222001424	CO

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
276	Promethazine 25mg tablet; 100 tablets		Pack of 100 tablets	597 463		597 463	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Receptozine 25 mg	R85.10	Pack of 100 tablets	14	20	96.24	189710049	CO
277	Propranolol 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	349 038		349 038	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	INDOBLOK 10	R4.61	Pack of 28 tablets	14	50	90.00	181798180	CO
278	Propranolol 10mg tablet; 50 tablets		Pack of 50 tablets	175 666		175 666	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 10 mg	R6.46	Pack of 50 tablets	14	100	96.24	189716004	CO
279	Propranolol 10mg tablet; 84/90 tablets		Pack of 84/90 tablets	162 656		162 656	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 10 mg	R8.68	Pack of 84 tablets	14	100	96.24	181798181	CO
280	Propranolol 40mg tablet; 56/60 tablets		Pack of 56/60 tablets	108 348		108 348	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 40 mg	R12.64	Pack of 56 tablets	14	100	96.24	189711802	CO
281	Propranolol 40mg tablet; 84/90 tablets		Pack of 84/90 tablets	36 054		36 054	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 40 mg	R18.04	Pack of 84 tablets	14	100	96.24	180190493	CO
282	Pyridostigmine 10mg tablet; 50 tablets		Pack of 50 tablets	48 599		48 599	100.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	MESTINON 10 MG	R279.49	Pack of 50 tablets	14	10	90.00	180000607	CO
283	Pyridostigmine 60mg tablet; 150 tablets		Pack of 150 tablets	33 394		33 394	100.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	MESTINON 60 MG	R1 249.00	Pack of 150 tablets	14	10	90.00	189710277	CO
284	Pyridoxine (Vitamin B6) 25mg tablet; 100 tablets		Pack of 100 tablets	363 090		145 236	40.00%	Portfolio Pharmaceuticals (Pty) Ltd	MAAA0039590	VWB81	Portfolio Pyridoxine HCL 25mg	R7.75	Pack of 100 tablets	14	300	90.00	189710278	CO
						217 854	60.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Pyridoxine 25mg Gulf	R8.03	Pack of 100 tablets	14	300	86.75		
285	Pyridoxine (Vitamin B6) 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	28 964 502		14 482 251	50.00%	Portfolio Pharmaceuticals (Pty) Ltd	MAAA0039590	VWB81	Portfolio Pyridoxine HCL 25mg	R2.95	Pack of 28 tablets	14	300	90.00	180339610	PG
						1 296 756	4.48%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Pyridoxine 25mg Gulf	R3.05	Pack of 28 tablets	14	300	86.95		
287	Quetiapine 100mg tablet; 90 tablets	Class 20	Pack of 90 tablets	161 434		161 434	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Quetiapine 100 MSQ	R35.62	Pack of 90 tablets	14	10 x 90s	92.33	180351237	CO
289	Quetiapine 200mg tablet; 60 tablets	Class 21	Pack of 60 tablets	170 208		170 208	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Quetiapine 200 MSQ	R40.08	Pack of 60 tablets	14	10 x 60s	90.08	180351239	CO
290	Quetiapine 25mg tablet; 100 tablets		Pack of 100 tablets	155 933		155 933	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Sizocam 25 mg	R16.99	Pack of 100 tablets (10 x 10)	14	1	90.00	180350983	CO
292	Quetiapine 300mg tablet; 60 tablets	Class 22	Pack of 60 tablets	48 084		48 084	100.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	Quetiapine 300 MSQ	R53.66	Pack of 60 tablets	14	10 x 60s	97.60	181772178	CO
304	Risedronic acid 35mg tablet; 4 tablets	Class 5	Pack of 4 tablets	80 797		80 797	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Sandoz Risedronate 35	R13.95	Pack of 4 tablets	14	50	96.20	181786131	CO
306	Risperidone 0,5mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 134 242		1 020 818	90.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	RESKIT 0.5	R3.51	Pack of 30 tablets	14	200 x 30s	97.60	181799554	CO
307	Risperidone 1mg tablet; 28/30 tablets		Pack of 28/30 tablets	2 028 006		1 622 405	80.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	RESKIT 1	R4.50	Pack of 30 tablets	14	200 x 30s	97.60	180339003	CO
						405 601	20.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Risperidone 1 Unimed	R5.12	Pack of 28 tablets	14	200	83.84		
308	Risperidone 2mg tablet; 28/30 tablets		Pack of 28/30 tablets	2 974 482		2 379 586	80.00%	LHC Pharmaceuticals (Pty) Ltd	MAAA0443063	VREJ7	RESKIT 2	R4.68	Pack of 30 tablets	14	200 x 30s	97.60	180965107	CO
						594 896	20.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Risperidone 2 Unimed	R5.36	Pack of 28 tablets	14	200	83.16		
309	Risperidone 3mg tablet; 28/30 tablets		Pack of 28/30 tablets	1 334 086		1 334 086	100.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Risperidone 3 Unimed	R6.96	Pack of 28 tablets	14	200	96.24	222001854	CO
310	Rivaroxaban 10mg tablet; 30 tablets [Items 310 + 311 +312 will be considered a series]	Class 28 In a series with Class 27	Pack of 30 tablets	153 968		153 968	100.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	REXARAV 10 MG	R31.09	Pack of 30 tablets	14	48	90.00	181870433	CO
311	Rivaroxaban 15mg tablet; 42 tablets [Items 310 + 311 +312 will be considered a series]	Series 2	Pack of 42 tablets	15 756		15 756	100.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	REXARAV 15 MG	R39.52	Pack of 42 tablets	14	60	90.00	222001163	CO
312	Rivaroxaban 20mg tablet; 28/30 tablets [Items 310 + 311 +312 will be considered a series]	Class 27 in a series with Class 28	Pack of 28/30 tablets	157 210		157 210	100.00%	Viatrix Healthcare (Pty) Ltd	MAAA0081441	V3PS6	REXARAV 20 MG	R30.42	Pack of 30 tablets	14	48	90.00	222001855	CO
315	Rosuvastatin 10mg tablet; 28/30 tablets	Class 31	Pack of 28/30 tablets	2 842 540		1 989 778	70.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Rosuvastatin 10 Unimed	R7.52	Pack of 28 tablets	14	200	96.00	222001127	CO
						852 762	30.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9V1	Rosuvakem 10	R7.50	Pack of 30 tablets (3 x 10)	14	1	90.00		
316	Rosuvastatin 5mg tablet; 28/30 tablets	Class 30	Pack of 28/30 tablets	17 853 515		6 418 702	35.95%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Rosuvastatin 5 Unimed	R5.39	Pack of 28 tablets	14	300	96.24	222001128	CO
						6 112 573	34.24%	Smart Pharmaceuticals (Pty) Ltd	MAAA1003704	V2CW0	Rosuvastatin 5mg Smart	R5.77	Pack of 28 tablets	14	200	91.65		
						5 322 240	29.81%	Ruby Pharmaceuticals (Pty) Ltd	MAAA0562340	VG1F0	Rubistor 5 mg	R6.36	Pack of 30 tablets	14	240	79.80		
317	Senna extract equivalent to Sennosides A and B 13,5mg tablet; 20 tablets		Pack of 20 tablets	3 432 415		3 432 415	100.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	Soflax Tablets	R5.35	Pack of 20 tablets	14	480	90.00	181826115	CO
322	Sildenafil 50mg scored tablets; 4 tablets	Class 23	Pack of 4 tablets	140 671		140 671	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Religra 50mg	R3.98	Pack of 4 tablets	14	80	90.00	222001856	CO
326	Simvastatin 10mg tablet; 28/30 tablets	Class 29	Pack of 28/30 tablets	34 794 460	38 324 899	10 520 046	27.45%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Lipidex 10	R4.34	Pack of 28 tablets	14	200	96.20	189762856	CO
						9 707 531	25.33%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unisim 10	R4.70	Pack of 28 tablets	14	200	88.77		
						9 343 375	24.38%	Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VSSS4	ROLTESIM 10	R4.56	Pack of 30 tablets	14	200	85.44		
						8 753 947	22.84%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Simvastatin 10 mg 28's	R4.82	Pack of 28 tablets	14	10	80.05		
329	Spironolactone 100mg tablet; 60 tablets		Pack of 60 tablets	10 905		10 905	100.00%	Pharmacare Limited	MAAA0008452	V2205	SPIRACTIN 100MG TAB SEC 60 - T	R145.95	Pack of 60 tablets	14	10	90.00	189711050	CO
330	Spironolactone 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	4 683 132		2 809 879	60.00%	Pharmacare Limited	MAAA0008452	V2205	SPIRACTIN 25MG TAB B/BAG 28	R12.79	Pack of 28 tablets	14	60	90.00	181798184	PG
						1 873 253	40.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Spironolactone 25 Kiara	R12.98	Pack of 30 tablets	14	100	88.66		
331	Spironolactone 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	2 206 940		1 765 552	80.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Spironolactone 25 Kiara	R22.20	Pack of 56 tablets	14	100	90.00	181747912	CO
						441 388	20.00%	Pharmacare Limited	MAAA0008452	V2205	SPIRACTIN 25MG TAB B/BAG 56	R25.06	Pack of 56 tablets	14	40	78.41		
332	Spironolactone 25mg tablet; 84/90 tablets		Pack of 84/90 tablets	163 635		163 635	100.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Spironolactone 25 Kiara	R33.67	Pack of 84 tablets	14	50	90.00	181747914	CO

Item No	Item Specification	Therapeutic / Procurement Class Number / Series Number	Unit as Advertised	Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
333	Sulfasalazine 500mg tablet; 100 tablets		Pack of 100 tablets	377 054		3 456	0.92%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Salazopyrin EN 500mg TAB, 100s	R309.57	Pack of 100 tablets	14	1	90.00	189714546	CO
339	Theophylline 200mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	1 664 949		1 664 949	100.00%	Kiara Health (Pty) Ltd	MAAA0537011	VSTP3	Theophylline Anhydrous 200 Kiara	R34.50	Pack of 60 tablets	14	50	90.00	189762882	CO
340	Thiamine (Vitamin B1) 100mg tablet; 28/30 tablets		Pack of 28/30 tablets	6 221 076		3 200 000	51.44%	Portfolio Pharmaceuticals (Pty) Ltd	MAAA0039590	VWB81	Portfolio Thiamine HCl 100mg	R6.30	Pack of 28 tablets	14	500	90.00	181798189	PG
341	Thiamine (Vitamin B1) 100mg tablet; 84/90 tablets		Pack of 84/90 tablets	41 653		41 653	100.00%	Portfolio Pharmaceuticals (Pty) Ltd	MAAA0039590	VWB81	Portfolio Thiamine HCl 100mg	R18.50	Pack of 84 tablets	14	108	90.00	181917416	CO
342	Topiramate 100mg tablet; 56/60 tablets		Pack of 56/60 tablets	44 552		44 552	100.00%	Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Epitoz 100	R40.94	Pack of 60 tablets	14	100	90.00	180208573	CO
344	Topiramate 25mg tablet; 56 tablets		Pack of 56 tablets	64 478		64 478	100.00%	Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Epitoz 25	R20.78	Pack of 60 tablets	14	50	90.00	180208565	CO
345	Topiramate 50mg tablet; 56 tablets		Pack of 56 tablets	78 544		78 544	100.00%	Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Epitoz 50	R26.17	Pack of 60 tablets	14	100	90.00	180208570	CO
346	Tramadol 50mg capsule/tablet; 100 tablets/capsules		Pack of 100 tablets/capsules	3 381 783		3 043 605	90.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Tramadol Unimed	R21.15	Pack of 100 capsules	14	48	96.24	222001422	CO
						338 178	10.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Tramadol 50 mg	R25.70	Pack of 100 capsules	14	6	70.64		
347	Tramadol 50mg capsule/tablet; 20 capsules/tablets		Pack of 20 capsules/tablets	10 038 654		9 034 789	90.00%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Tramadol Unimed	R4.72	Pack of 20 capsules	14	150	96.24	222001423	CO
						1 003 865	10.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Tramadol 50 mg	R5.58	Pack of 20 capsules	14	10	73.60		
348	Tramadol 100mg capsule/tablet; 60 capsules/tablets		Pack of 60 capsules/tablets	305 682		305 682	100.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Tramadol SR 100MG Austell	R44.85	Pack of 60 tablets	14	6	90.00	181761190	CO
351	Tranexamic acid 500mg tablet; 100 tablets		Pack of 100 tablets	9 696		9 696	100.00%	Emcure Pharmaceuticals SA (Pty) Ltd	MAAA0050669	V3GQ7	Emkapron 500	R298.33	Pack of 100 tablets	14	10	90.00	189718982	CO
352	Tranexamic acid 500mg tablet; 30 tablets		Pack of 30 tablets	411 284		411 284	100.00%	Emcure Pharmaceuticals SA (Pty) Ltd	MAAA0050669	V3GQ7	Emkapron 500	R89.50	Pack of 30 tablets	14	10	90.00	222000951	CO
356	Valproate sodium 133,2mg and Valproic acid 58mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	2 753 153		825 946	30.00%	Ruby Pharmaceuticals (Pty) Ltd	MAAA0562340	VG1F0	Rubilim CR 200	R44.49	Pack of 60 tablets	14	30	96.00	181813970	CO
						1 927 207	70.00%	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 200MG 56'S	R45.14	Pack of 56 tablets	14	30	88.69		
357	Valproate sodium 199,8mg and Valproic acid 87mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	4 556 064		1 822 426	40.00%	Ruby Pharmaceuticals (Pty) Ltd	MAAA0562340	VG1F0	Rubilim CR 300	R56.30	Pack of 60 tablets	14	20	94.47	181813972	CO
						2 733 638	60.00%	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 300MG 56'S	R55.36	Pack of 56 tablets	14	20	90.00		
358	Valproate sodium 333mg and Valproic acid 145mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	5 005 407		1 001 081	20.00%	Ruby Pharmaceuticals (Pty) Ltd	MAAA0562340	VG1F0	Rubilim CR 500	R83.82	Pack of 60 tablets	14	20	96.00	181813974	CO
						4 004 326	80.00%	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 500MG 56'S	R88.16	Pack of 56 tablets	14	20	85.34		
361	Venlafaxine 150mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	146 902		146 902	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	VEXINE 150 mg	R52.62	Pack of 30 capsules	14	3 pack	90.00	180358282	CO
362	Venlafaxine 37,5mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	35 847		35 847	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	VEXINE 37,5 mg	R20.43	Pack of 30 capsules	14	3 pack	90.00	181851983	CO
363	Venlafaxine 75mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	143 027		143 027	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	VEXINE 75 mg	R27.35	Pack of 30 capsules	14	3 pack	90.00	180358280	CO
364	Verapamil 240mg tablet; 28/30 tablets		Pack of 28/30 tablets	42628		42 628	100.00%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	VERAHEXAL 240MG 30S PRT	R74.41	Pack of 30 tablets	14	50	90.00	189709075	CO
365	Verapamil 40mg tablet; 84/90 tablets		Pack of 84/90 tablets	97 304		97 304	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Verapamil 40 Oethmaan	R32.50	Pack of 84 tablets	14	10	96.20	180339609	PG
366	Warfarin 5mg scored tablet; 100 tablets		Pack of 100 tablets	393 772		393 772	100.00%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Warfarin 5mg 100's Austell	R30.99	Pack of 100 tablets	14	6	90.00	189759084	CO
367	Zinc 20mg tablet; 10 tablets		Pack of 10 tablets	294 488		294 488	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Zinc 20mg Gulf	R4.21	Pack of 10 tablets	14	300	90.00	181896936	CO
368	Zinc 20mg tablet; 100 tablets		Pack of 100 tablets	185 705		185 705	100.00%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	Zinc 20mg Gulf	R11.07	Pack of 100 tablets	14	50	90.00	181862059	CO

LEGEND UNIT OF MEASURE (UOM)	
BT	Bottle
CO	Container
PG	Packaging Group (Patient Ready Pack)
PK	Prepack



SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP09-2026SD

**SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH
FOR THE PERIOD 01 MAY 2026 TO 30 APRIL 2029**

BID VALIDITY PERIOD: 180 DAYS

BID ADVERT DATE: 6 JUNE 2025

**CLOSING DATE AND TIME OF BID:
4 AUGUST 2025 AT 11H00**

NON-COMPULSORY ONLINE BRIEFING SESSION:

MS TEAMS WEBINAR: 20 JUNE 2025 @ 10H00



Table of Contents

1. ABBREVIATIONS	5
2. DEFINITIONS	6
SECTION A	12
3. BID DOCUMENT CHECK LIST	12
3.1.1. LEGISLATIVE AND REGULATORY FRAMEWORK	18
3.1.2. BID INFORMATION SESSION	18
3.1.3. EVALUATION CRITERIA	19
4. PHASE I: ADMINISTRATIVE EVALUATION	19
4.1. BID DOCUMENTS	20
4.2. CONSORTIUMS, JOINT VENTURE (INCORPORATED OR UNINCORPORATED), AND PARTNERSHIPS	21
4.3. TAX COMPLIANCE STATUS	23
5. PHASE II: PRODUCT TECHNICAL EVALUATION: LEGAL AND REGULATORY	24
5.1. LEGISLATIVE REQUIREMENTS RELATING TO THIS BID	24
5.1.1 LICENSING REQUIREMENTS	24
5.1.2 MEDICINE REGISTRATION CERTIFICATE (MRC) REQUIREMENTS AND VARIATION SUMMARIES	26
5.1.4 AUTHORISATION DECLARATION (PBD1.2)	27
5.1.5 SAMPLES TO BE SUBMITTED TO SAMPLE EVALUATION SITES	27
5.1.6 COMPLIANCE WITH SPECIFICATIONS	29
6. PHASE III: PRICE AND PREFERENCE POINTS EVALUATION	29
6.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS CLAIMED IN TERMS OF THE REVISED PREFERENTIAL PROCUREMENT REGULATIONS (PPPFA), 2022	29
6.1.1. HDI AND RDP GOAL POINTS CLAIMABLE FOR THIS TENDER	30
6.1.2. HDI CLAIMS MADE IN SBD 6.1 MUST BE SUPPORTED BY EVIDENCE BASED DOCUMENTATION	30
6.1.2.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS FOR HDI.	31
6.1.3. RDP GOAL: PROMOTION OF SOUTH AFRICAN OWNED ENTERPRISES	33
6.1.3.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS	33
6.1.4. POINTS CLAIMABLE	33
6.2. HDI CLAIMS IN CONSORTIUMS, UNINCORPORATED JOINT VENTURES AND PARTNERSHIPS	34
6.2.1. FORMULAE - PREFERENCE POINT SYSTEM TO BE APPLIED IN THIS TENDER	35
6.2.2. FORMULA FOR PRICE (90)	35
6.2.3. FORMULA FOR HDI PREFERENCE POINTS (10)	36
7. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS	36
8. VALUE ADDED TAX	37



9. SUBMISSION OF BIDS	37
10. COMPLETION OF DOCUMENTS AND BID SUBMISSION	38
11. LATE BIDS.....	41
12. COUNTER CONDITIONS.....	41
13. FRONTING	41
14. SUPPLIER DUE DILIGENCE	42
15. COMMUNICATION.....	42
16. CONTACT DETAILS.....	43
SECTION B	44
17. CONTRACT PERIOD	44
18. PARTICIPATING AUTHORITIES	44
19. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES.....	45
20. AWARD CONDITIONS	45
20.1. SPLIT AND MULTIPLE AWARDS.....	46
20.2. THERAPEUTIC CLASS AWARDS.....	47
20.3. SERIES AWARDS	55
20.4. PROCUREMENT CLASS	57
20.5. REFERENCE PRICING.....	57
20.6. NEGOTIATIONS	58
20.7. NON-COMMITMENT.....	58
21. POST AWARD CONDITIONS	59
22. PRICE REVIEW.....	59
22.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS.....	60
22.2. INSTRUCTIONS FOR PRICE BREAKDOWN	60
22.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK	61
22.4. APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS.....	62
22.4.1. EXCEPTIONAL PRICE ADJUSTMENTS BEFORE START OF CONTRACT	63
22.4.2. ROUTINE PRICE ADJUSTMENTS	63
22.4.3. EXCEPTIONAL PRICE ADJUSTMENTS DURING CONTRACT PERIOD	64
22.5. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW	65
23. QUALITY.....	65
24. DELIVERY AND QUANTITIES	65
24.1. DELIVERY BASIS.....	65
24.2. QUANTITIES.....	66
SECTION C.....	67
25. SUPPLIER PERFORMANCE MANAGEMENT.....	67
25.1. COMPLIANCE WITH REPORTING REQUIREMENTS:.....	67
25.3 ORDER PLACEMENT AND DELIVERY:.....	68
25.4 ORDER CANCELLATIONS AND SUBSTITUTION:.....	69
25.5 IRRATIONAL OR MISALIGNED ORDERS:.....	69



25.6 DELIVERY ADHERENCE	69
25.7 CONTINUITY OF SUPPLY	70
26. REPORTING.....	73
27. PACKAGING, LABELLING AND BARCODES	73
27.1. PACKAGING	73
27.2. LABELLING	74
27.3. BARCODES	75
28. SHELF LIFE.....	75
29. DISCONTINUATION OF CONTRACTED PRODUCT SUPPLY	76
30. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS.....	77
31. CANCELLATION OF CONTRACT.....	77
32. THIRD PARTIES.....	77



1. ABBREVIATIONS

API	:Active Pharmaceutical Ingredient
BAC	:Bid Adjudication Committee
BAU	:Business as Usual
CPA	:Contract Price Adjustment
CIPC	:Companies and Intellectual Property Commission
CSD	:Central Supplier Data base
DVP	:Digital Variation Portal
EAN	:European Article Numbering
EU	:European Union
GMP	:Good Manufacturing Practice
HDI	:Historically Disadvantaged Individual
ID	:Identification Document
IVD	:In vitro diagnostic
MCC	:Medicines Control Council
MHPL	:Master Health Products List
MRC	:Medicine Registration Certificate
NDoH	:National Department of Health
PBD	:Pharmaceutical Bidding Documents
PI	:Package Insert
PPPFA	:Preferential Procurement Policy Framework Act
RoE	:Rate of Exchange
RDP	:Reconstruction and Development Programme
SAHPRA	:South African Health Products Regulatory Authority
SARS	:South African Revenue Service
SBD	:Standard Bidding Document
SEP	:Single Exit Price
SRCC	:Special Requirements Conditions of Contract
VAT	:Value Added Tax



2. DEFINITIONS

Unless otherwise specified in this SRCC, any word or expression defined in the applicable Act retains the same meaning within this document, where -

- (1) “Complementary medicine” means any substance or mixture of substances that-
 - (a) originates from plants, fungi, algae, seaweeds, lichens, minerals, animals or other substance as determined by SAHPRA.
 - (b) is used or purporting to be suitable for use or manufactured or sold for use
 - (i) in maintaining, complementing or assisting the physical or mental state; or
 - (ii) to diagnose, treat, mitigate, modify, alleviate or prevent disease or illness or the symptoms or signs thereof or abnormal physical or mental state of a human being or animal; and
 - (c) is used-
 - (i) as a health supplement; or
 - (ii) in accordance with those disciplines as determined by SAHPRA.
- (2) “Consortium” means a contractual collaboration between two or more separate legal entities who combine resources or expertise for a specific tender or project, without forming a new legal entity.
- (3) “Contract” means the agreement that results from the acceptance of a tender.
- (4) “Disability” means, in respect of a person, a permanent impairment of a physical, intellectual, or sensory function, which results in restricted, or lack of, ability to perform an activity in the manner, or within the range, considered normal for a human being.
- (5) “Health supplement” means any substance, extract or mixture of substances as determined by SAHPRA, sold in dosage forms used or purported for use in restoring, correcting or modifying any physical or mental state by-
 - (a) complementing health.



- (b) supplementing the diet; or
 - (c) a nutritional effect, and excludes injectable preparations, medicines or substances listed as Schedule 1 or higher in the Medicines Act.
- (6) “Historically Disadvantaged Individual (HDI)” means a South African citizen –
- (i) who, due to the apartheid policy that had been in place, had no franchise in national elections prior to the introduction of the Constitution of the Republic of South Africa, 1983 (Act No 110 of 1983) or the Constitution of the Republic of South Africa, 1993 (Act No 200 of 1993) (“the Interim Constitution”); and / or
 - (ii) who is a female; and / or
 - (iii) who has a disability:
- Provided that a person who obtained South African citizenship on or after the coming to effect of the Interim Constitution, is deemed not to be an HDI.
- (7) “IVD” (in vitro diagnostic) means a medical device, whether used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring or compatibility purposes.
- (8) “Joint Venture (Incorporated)” means a distinct legal entity formed through the joint ownership of two or more parties, established for contractual collaboration and registered with the Companies and Intellectual Property Commission (CIPC).
- (9) “Joint venture (Unincorporated)” means a project- or bid-specific contractual collaboration between two or more entities, established without creating a separate legal entity.
- (10) "Label", when used as a verb, means brand, mark or otherwise designate or describe, and when used as a noun, means any brand or mark or any written, pictorial, or other descriptive matter appearing on or attached to or packed with and referring to any article or the package containing any article.



- (11) "Locally produced product" refers to a product whose formulation and conversion processes, including the use of materials and components to manufacture medicines, occur within the Republic of South Africa. This includes active pharmaceutical ingredients (APIs) (imported or locally produced) and excipients to produce finished products. Locally produced product includes **the fill and finish of sterile products** (including vaccines) but **excludes the fill, finish, and packaging of products such as solids, liquids, sterile drops and semi-solid dosage forms.**
- (12) "Management" in relation to an enterprise or business, means an activity inclusive of control and performed daily, by any person who is a principal executive officer of the company, by whatever name that person may be designated, and whether or not that person is a director.
- (13) "manufacture" means all operations including purchasing of material, processing, production, packaging, quality control, release and storage of medicinal products and related control.
- (14) "medical device" means any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, including Group III and IV Hazardous Substances contemplated in the Hazardous Substances Act, 1973 (Act No. 15 of 1973)—
- (a) intended by the manufacturer to be used, alone or in combination, for humans or animals, for one or more of the following:
- (i) diagnosis, prevention, monitoring, treatment or alleviation of disease;
 - (ii) diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
 - (iv) investigation, replacement, modification or support of the anatomy or of a physiological process;
 - (iv) supporting or sustaining life;
 - (v) control of conception;
 - (vi) disinfection of medical devices; or
 - (vii) providing information for medical or diagnostic purposes by means of in vitro examination of specimens derived from the human body; and



(b) which does not achieve its primary intended action by pharmacological, immunological or metabolic means, in or on the human or animal body, but which may be assisted in its intended function by such means;

All medical devices are categorized based on the risk associated with the intended use of the medical device or IVD. Medical devices, including in-vitro diagnostic (IVD) medical devices and non-IVD medical devices, are grouped into four classes including Class A devices presenting the lowest potential risk (e.g. a tongue depressor) and Class D devices presenting the greatest potential risk (e.g. pacemakers) to patients, users and public health.

	RISK	NON-IVD EXAMPLES	IVD EXAMPLES	PHASE II REQUIREMENTS
Class A	Low individual risk & minimal or no public health risk	Surgical retractors/ tongue depressors	Reagents, instruments, specimen receptacle. Microbiological culture medium	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs
Class B	Low-moderate	Hypodermic needle/ suction equipment	Pregnancy self-test kit, urine self-test strips to detect glucose, biochemistry test for gases, hormones, vitamins	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs
Class C	Moderate-high	Lung ventilators	Malaria rapid test, human genetic testing, STD test, Prenatal screening test, Tumour markers, self-monitoring blood glucose	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs



Special Requirements and Conditions of Contract HP09-2026SD

	RISK	NON-IVD EXAMPLES	IVD EXAMPLES	PHASE II REQUIREMENTS
Class D	High	Heart valves /Implantable defibrillator	Screening for HIV/Hepatitis B, detection of Rhesus markers; testing red blood cell antigen or antibodies within ABO blood group system	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs

- (15) "medical device or IVD establishment" means a facility used by a manufacturer, wholesaler, distributor, retailer, service provider or an importer of medical devices or IVDs for conducting business;
- (16) "medicine" means:
- (a) any substance or mixture of substances used or purporting to be suitable for use or manufactured or sold for use in
 - (i) the diagnosis, treatment, mitigation, modification or prevention of disease, abnormal physical or mental state or the symptoms thereof in humans; or
 - (ii) restoring, correcting or modifying any somatic or psychic or organic function in humans; and
 - (b) includes any veterinary medicine.
- (17) "Medicines Act" means the Medicines and Related Substances Control Act, 1965 (Act No. 101 of 1965).
- (18) "Minimum order quantity" means the fewest number of units a supplier is willing to sell to a single Participating Authority/Authorities in a single consignment.
- (19) "Package" means anything in or by which any medicine, complementary, veterinary medicines or scheduled substance is enclosed, covered, contained, or packed.
- (20) "Partnership" means a profit-driven arrangement between two or more persons, governed by the Partnership Act, 1939, and South African common law, in which the partners share liability and do not constitute a separate legal entity.



- (21) "Person" includes reference to a juristic person.
- (22) "Rand value" means the total estimated value of a contract in Rand denomination which is calculated at the time of tender invitations and includes all applicable taxes and excise duties.
- (23) "Single Exit Price" (SEP) is defined in the Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances, under the Medicines and Related Substances Act No 101 of 1965. It is the price set by the manufacturer or importer, including the logistics fee and VAT, and is calculated by multiplying the price of the lowest unit of the medicine or substance by the number of units in the pack.
- (24) "Tender" means a written offer or bid in a prescribed or stipulated form in response to an invitation by an organ of state for the provision of services or goods.
- (25) "Third party manufacturer" refers to any external company or organisation, other than the holder of the Medicines Registration Certificate (MRC), that is responsible for manufacturing the product as indicated on the MRC for the item being offered in the bid. Where such a manufacturer is involved, the bidder must have formal legal agreement in place with the third party and must submit a signed Authorisation Declaration (PBD1.2) from the third party involved.
- (26) "Working days" for the purpose of this document working days refer to Monday to Friday only excluding public holidays.



SECTION A

3. BID DOCUMENT CHECK LIST

All bid documents listed below must be **compiled, indexed, and submitted** in the **exact sequence** specified.

Each document listed must be supported by the relevant annexure, if applicable.

All bid documents **must be duly signed** by a person **authorised to legally bind the bidder**.

Non-compliance with any of these requirements **may render a bid non-responsive**, resulting in **disqualification from further evaluation** in accordance with applicable procurement regulations.

The table below serves as a guide to the documents that should be included in the bid submission. While some documents are strongly recommended, they are not considered during the bid evaluation process, however, are required for administrative purposes. Adhering to the suggested compilation sequence is highly recommended.

The absence of mandatory documents will impact the bid's responsiveness. Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
1	CL	Covering Letter Note: Status relating to TAX, License to Manufacture, Certificates etc.	Administrative				
2	BFI	Bid/File Index.	Administrative				



Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
3	PBD3 & Resolution	Bid Signature Authority; Resolution/Authority to sign bid.	Mandatory				
4	SBD1	SBD 1: Invitation to bid.	Mandatory				
5	PBD4.1	PBD 4.1: Contact Details of Bidder.	Administrative				
6	Consortium	<ul style="list-style-type: none"> • Certified copy of relevant agreement between entities (SRCC Section 4.3) • And any other document as specified in Section 4.3 	Mandatory, if applicable				
7	JV (UNINCORPORATED)	<ul style="list-style-type: none"> • Certified copy of relevant agreement between entities (SRCC Section 4.3) • And any other document as specified in Section 4.3 	Mandatory, if applicable				
8	JV (INCORPORATED)	<ul style="list-style-type: none"> • Certified copy of CIPC registration certificate • Certified copy of relevant agreement (SRCC Section 4.3) • And any other document as specified in Section 4.3 	Mandatory, if applicable				
9	PARTNERSHIP	<ul style="list-style-type: none"> • Certified copy of relevant agreement between entities (SRCC Section 4.3) • And any other document as specified in Section 4.3 	Mandatory, if applicable				
10	CSD	CSD Registration report	Mandatory				
11	TCP	SARS Tax Clearance Pin	Mandatory				
12	CIPC	CIPC/CIPRO company registration certificate	Mandatory				
13	NC	Proof of company ceding mergers, acquisition, and name changes	Administrative				



Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
14	PBD9.1	PBD9.1: Entity Directors Categorisation and entity ownership profile	Mandatory				
15	ID	Certified copies of Directors/Owners Identification listed in PBD9-2025	Mandatory				
16	SBD4	SBD 4: Declaration of interest	Mandatory				
17	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.	Mandatory				
18	SBD6	SBD 6(1) Indicate Preference Points Claimed in table and space provided.	Mandatory				
19	OWNERSHIP	Company Ownership Organogram	Mandatory, if claiming preferential points				
20	SHARES	Certified Share Register and Share Certificate(s) of HDI member/s	Mandatory, if claiming preferential points				
21	TRUST DEED	Trust /Scheme Deed listing HDI Trustees Beneficiaries and with stipulated benefit. Certified copy required	Mandatory, if applicable and preferential points claimed				
22	HDI ID	ID's of HDI with equity ownership (had no franchise in national elections before the 1983 and 1993 Constitutions). Certified copies required	Mandatory, if claiming preferential points				
23	ID-DISABILITY	ID of HDI disability claimed in SBD 6.1 Certified copies required	Mandatory, if claiming preferential points				
24	DR-NOTE	Medical Certificate detailing the nature and extent of the disability as claimed in SBD 6.1. Certified copies required	Mandatory, if applicable and preferential points claimed				



Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
25	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.	Mandatory				
26	GMP-LM	SAHPRA approved GMP certificate as alternative to PBD5 (Local manufacturers)	Mandatory				
27	SBD5	SBD5: The National Industrial Participation Programme.	Mandatory				
28	LICMI	Valid licence to manufacture or import (in the name of the bidder), <u>including all annexures</u> . Certified copies required.	Mandatory				
29	LICM	Valid licence to manufacture or import, <u>including all annexures for local manufacturing sites</u> as listed on the MRC of the bidder (applicant). Certified copies required.	Mandatory				
30	LICCM	Valid licence to manufacture/import distribute/wholesale a Complementary Medicines (in the name of the bidder), <u>including all annexures and DA02 product list</u> : Certified copies required	Mandatory				
31	LICMD	Valid licence to manufacture/import distribute/wholesale a medical device or an in vitro diagnostic (IVD) (in the name of the bidder), <u>including all annexures</u> : Certified copies required	Mandatory				



Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
32	MRC	Valid Medicine Registration Certificates (MRC). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.	Mandatory				
33	MRC Annexures	MRC Annexures must be submitted only for newly registered products. Note: The conditions of registration must align with the MRC of the newly registered medicine and must be clearly marked.	Administrative				
34	VARSUM	A valid Variation Summary for any changes on the MRC where applicable as prescribed by SAHPRA GUIDELINE: BAU VARIATIONS COMMUNICATION, latest version - Certified copies	Administrative				
35	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.	Administrative				
36	PBD1.1	PBD 1.1: List of products offered sourced from third party.	Administrative				
37	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party OR alternatively a formal letter from the third party could be included.	Administrative				
38	PI	The original Package Insert (PI), QR code with professional information approved by the MCC or SAHPRA must be submitted for each product offered. Each PI must be clearly marked with the relevant item	Administrative				



Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
		number and arranged in numerical order.					
39	PS	Proof of sample submission.	Administrative				
40	BL	Bidder's item list (list of products offered).	Administrative				
41	PRICE	Signed Excel Bid Response i.e. Pricing Schedule. <u>Note: If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.</u>	Mandatory				
42	USB	Set 2 & 3 - Universal Serial Bus (USB) Flash Drive / Storage Device with digital copy of the completed bid. Note: Each compilation sequence (document) must be saved as a separate file, with index admin code abbreviations used in each file name.	Administrative				

All bid documents listed above must be sorted, filed, and submitted in the exact order as indicated above

Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.

The bid document check list is available as Annexure A in an excel spreadsheet format and should be completed by all bidders and submitted in hard copy and as part of the electronic copies of "Set 3: Electronic version of bid documents"

The NDoH reserves the right to request any non-mandatory bid document or information for clarification, if it does not change the substance of the bid. The bidder will have seven (7) working days to submit the requested document or information.

Digital copies must be identical to hard copy submissions. In the event of a discrepancy, the hard copy takes precedence over the digital copy.



3.1.1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all resulting contracts shall be governed by the applicable provisions of the following legislation:

- The Medicine and Related Substances Act, 1965 (Act 101 of 1965).
- The Pharmacy Act, 1974 (Act 53 of 1974).
- The Patents Act, 1978 (Act 57 of 1978), where applicable to intellectual property rights in procurement.
- The Trademarks Act, 1993 (Act 194 of 1993), where relevant to product identification and branding.
- The General Conditions of Contract (GCC), issued in accordance with Treasury Regulation 16A under the Public Finance Management Act, 1999 (Act 1 of 1999).

The Special Requirements and Conditions of Contract (SRCC) shall supplement the GCC. In the event of any conflict between the SRCC and the GCC, the SRCC shall take precedence, except where such conflict contravenes applicable laws, regulations, or Treasury directives.

3.1.2. BID INFORMATION SESSION

A non-compulsory online briefing session will be held via an MS Teams Webinar on 20th June 2025 at 10H00. Bidders who wish to participate are required to register on MS Teams Webinar no later than Thursday, close of business, 19th June 2025, by using the following link.

<https://events.teams.microsoft.com/event/eff5eeda-cd16-4fc0-ab12-777d84dd69aa@a517371c-f316-484c-ac5c-98b76127790a>

Upon successful registration you will receive a confirmation email of your attendance.



If you experience any challenges with the registration process, please notify the Department via tenders@health.gov.za before 19th of June 2025.

It is strongly **recommended** that all prospective bidders submit all enquiries related to the advertised tender to tenders@health.gov.za . Prospective bidders must submit all enquiries on time to allow the response to reach the bidders before the tender closes.

3.1.3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

PHASE I	PHASE II	PHASE III	PHASE IV
Administrative evaluation	Product technical evaluation: Legal and regulatory	Price and Preference Points evaluation	Recommendation and Award
Bidders will be assessed for compliance with the mandatory administrative requirements	Bidders will be evaluated for compliance with the technical mandatory requirements and the product will be evaluated for compliance to the specification.	Bidders will be evaluated w.r.t compliance to HDI and RDP Goals (Price and Preference Points) as per section 6 of this SRCC	Recommendation and award

4. PHASE I: ADMINISTRATIVE EVALUATION

Bidders are required to submit all applicable documents relevant to the bidding enterprise or in the event of a consortium, joint venture (incorporated or unincorporated), or partnership, as specified in section 4.3, by the closing date and time of the bid.

All bid documents that require signatures must be duly signed by the individual identified in PBD3 using preferably permanent black ink. Failure to comply with these requirements will result in the bid being declared administratively non-responsive.

The PBD3 must be accompanied by a certified resolution from the board / members/ partners, confirming the authority to sign. The absence of the supporting resolution will render the bid non-responsive, regardless of the PBD3 being signed.



All copies of original documents, as requested in this bid, must be certified, and dated by the Commissioner of Oaths. (No copies of certified copies will be accepted).

4.1. BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the price, mandatory response fields, the excel bid response documents i.e. pricing schedule and Categorization of Directors Profile.

PBD9.1: Director's Categorization and entity ownership profile

The form attached as PBD9.1 in excel format, forms an integral part of the bid document. Bidders must ensure that it is completed without changing the structure thereof. All columns must be completed in full, and all pages signed. **Attach certified copies of Director/s identification documents (IDs).**

Excel Bid Response i.e., Pricing schedule:

Bidders are required to submit fully completed and responsive bids by accurately completing all mandatory fields in the Excel Bid Response Document, including pricing information. All prices must be quoted to two (2) decimal places.

Quoted prices must be all-inclusive (including VAT) and reflect the total cost for supply and delivery to the specified destination. The bid price for each product will be deemed applicable to the pack size and unit of measure as specified in the item description.

Bidders are strongly advised to consult the "Definition of Fields" document included in the Bid Response Document for detailed guidance on completing each field correctly. Incomplete or inaccurate submissions, particularly the omission of mandatory fields, may result in the bid being deemed non-responsive and disqualified.



Delivered Bid Prices offered.

Final prices submitted must **not exceed** the most recent Single Exit Price (SEP) as recorded on the National Department of Health (NDoH) SEP database.

If the prices submitted at the date and time of bid closure exceed the ex-manufacturer component of the SEP, inclusive of VAT, price negotiations will be required, where applicable, in accordance with the relevant regulations.

If, following negotiations, the bidder offers a price below or equal to the Single Exit Price, the award may be considered. However, the bidder will only qualify for contractual price adjustments up to the most recent Single Exit Price as recorded in the National Department of Health (NDoH) SEP Database.

4.2. CONSORTIUMS, JOINT VENTURE (INCORPORATED OR UNINCORPORATED), AND PARTNERSHIPS

If the bidder is not the applicant as required in section 5.2, but any of the following conditions apply, a signed agreement between the bidder and the applicant must be included in the bid submission. This applies in the following cases:

- The bidder is not the applicant on the MRC, but both the bidder and the applicant are subsidiaries of a single legal entity (same parent company).
- The bidder is not the applicant on the MRC, but either the bidder or the applicant is fully or partially owned by the other.



- The bidder is not the applicant on the MRC, but the bidder and the applicant are part of a technology transfer arrangement.

In such cases, the following documentation **must** be included with the bid:

- A certified copy of the signed agreement between the bidder and the applicant, outlining the terms of their relationship.
- PBD 3 must be completed, and the appointed representative must be authorised to act on behalf of the consortium, joint venture (incorporated or unincorporated), or partnership.

Additionally, all parties involved in the consortium, joint venture (incorporated or unincorporated) or partnership **must** submit the relevant legislative and mandatory documentation as required for this bid, as specified in the SRCC (Special Requirements and Conditions of Contract).

Each entity (participant) in the consortium joint venture (incorporated or unincorporated), or partnership **must** submit all mandatory documents including the following:

- Tax Compliance Status (TCS) PIN.
- Proof of Central Supplier Database (CSD) registration (CSD report).

While additional documents issued by the Companies and Intellectual Property Commission (**CIPC**) may be submitted, the inclusion of these two specific forms is mandatory.

- Registration certificate (Form CoR 14.3)
- Notice of change of Directors (Form CoR 39)

The following documents are mandatory for all parties involved in consortium, joint venture (incorporated or unincorporated), or partnership.:

- A valid license to manufacture (bidder and applicant), along with certified copies as per section 5.1, must be provided for all parties involved in the bid.



- An **MRC** (Medicines Registration Certificate) as per section 5.2, where **one of the parties** in the consortium, joint venture (incorporated or unincorporated) or partnership is identified as the applicant.

The bid must be submitted independently and without collusion or prior consultation with competitors. While communication within a consortium, joint venture (incorporated or unincorporated) or partnership is allowed, sharing bid details with external competitors constitutes **collusive bidding**, which is prohibited.

4.3. TAX COMPLIANCE STATUS

Bidders must be registered on the Government's Central Supplier Database (CSD) and include their full CSD report with their bid submission. The NDoH will verify the bidder's tax compliance status through the CSD.

The CSD and the Tax Compliance Status (TCS) PIN are the approved methods for verifying a bidder's tax compliance. Bidders must submit a valid TCS PIN with their bid. It is a condition of this bid that the bidder's tax matters are in order, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

If the bidder is found to be non-compliant with tax obligations during any stage of the evaluation process, the bidder will be notified of their non-compliance status. The bidder will be requested to submit, within seven (7) working days:

- a) Proof of tax compliance
- b) Proof must be provided that arrangements have been made with SARS to address any tax compliance issues, ensuring that the bid adjudication process is not delayed.

By submitting this bid, the bidder confirms that SARS may disclose the bidder's tax compliance status at any time during the contract period. Such confirmation is deemed granted by the bidder upon submission of the bid.



In the case of a consortium, joint venture (incorporated or unincorporated) or partnership, each party must be registered on the CSD, and their tax compliance status will be verified through the CSD, as described in section 4.3.

Bidders are responsible for ensuring that their CSD information is updated in accordance with the bid documents submitted.

Foreign suppliers, who do not have South African tax obligations or a history of doing business in South Africa, must complete the questionnaire on the SBD1 form. If a foreign bidder is recommended for award, the NDoH will submit the completed SBD1 to SARS at the email address: GovernmentInstitute@sars.gov.za. SARS will then issue a confirmation letter to the NDoH, confirming whether the foreign entity has any tax obligations in South Africa.

5. PHASE II: PRODUCT TECHNICAL EVALUATION: LEGAL AND REGULATORY

5.1. LEGISLATIVE REQUIREMENTS RELATING TO THIS BID

5.1.1 LICENSING REQUIREMENTS

The bidder offering a medicine:

- Must be the holder of a valid license to manufacture or import medicines, issued in terms of section 22C(1)(b) of the Medicines Act. The bidder must submit a certified copy of the original license, including all annexures.
- Additionally, if the bidder is offering a product manufactured locally, they must submit a certified copy of the original valid license to manufacture medicines, including all annexures, for all local manufacturing sites listed on the MRC.



The bidder offering a Class A, B, C, or Class D medical device or an in vitro diagnostic (IVD):

- Must be the holder of a valid license to manufacture, import, distribute, or wholesale medical devices or IVDs, issued in terms of section 22C(1)(b) of the Medicines Act, including all annexures. The bidder must submit a certified copy of the original license, including all annexures relevant to the products offered.
- An information leaflet for the unregistered medical device should be supplied, if required by SAHPRA.

The bidder offering Category D Complementary medicines:

- Must be the holder of a valid license to manufacture, import, or export Complementary medicines (Category D), issued in terms of section 22C(1)(b) of the Medicines Act, including the DA02 Product List as issued by SAHPRA. The bidder must submit a certified copy of the original valid license, including all annexures relevant to the products offered.
- An information leaflet for the complementary medicines should be supplied, if required by SAHPRA.

In the case of a consortium, joint venture (incorporated or unincorporated), and/or partnership.:

- All involved parties must be holders of the license to manufacture or import medicines, issued in terms of section 22C(1)(b) of the Medicines Act. Companies must submit certified copies of the respective licenses, as described in section 4.3.

If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths.



5.1.2 MEDICINE REGISTRATION CERTIFICATE (MRC) REQUIREMENTS AND VARIATION SUMMARIES

Items offered must be registered in terms of Section 15 of the Medicines Act and must comply with the conditions of registration for the duration of the contract.

- In the case of medicines, a certified copy of the original MRC, issued in terms of Section 15(3)(a) of the Medicines Act, must be included with the bid for each item offered.
- Where there is a variation in the MRC, the bidder should submit the Variation Summary.
- The bidder must be indicated as the applicant on each MRC.
- In the event that the bidder is not the applicant, refer to Section 4.3 regarding consortium, joint venture (incorporated or unincorporated), or partnership.
- In the event a product offered is not eligible for registration in terms of Section 15(3)(a) of the Medicines Act, refer to section 5.1.1 relating to Medical Devices, and Complementary medicine requirements.

5.1.3 SUBMISSION OF MRC ANNEXURES (CONDITIONS OF REGISTRATION)

Medicine registration may be subject to conditions as determined by SAHPRA in terms of Section 15(6)(a) of the Medicines Act. These conditions, as outlined in the MRC annexures (conditions of registration), should be submitted in the following instances:

- All newly registered medicines.
- Medicines for which a bid is being placed for the first time.
- In the event of a medicine review or renewal in terms of Section 15(6)(a) of the Medicines Act.

All bidders should submit, where applicable, a valid variation summary as prescribed by the latest version of the SAHPRA GUIDELINE: BAU VARIATIONS COMMUNICATION, along with a certified copy of the original MRC issued by the MCC/SAHPRA.



5.1.4 AUTHORISATION DECLARATION (PBD1.2)

Only the holder of a valid MRC issued in terms of the Medicines Act may submit a bid.

If the holder of the Medicines Registration Certificate (MRC) is not the manufacturer of the product offered in this bid, a third-party manufacturer authorisation is required. In such cases, the bidder must establish a formal legal agreement with the third-party manufacturer and submit a signed Authorisation Declaration (PBD1.2) from the relevant manufacturer as approved by SAPHRA which must be listed on the MRC.

The NDoH reserves the right to verify any information supplied by the bidder in the Authorisation Declaration. Should any information be found to be false or incorrect, the NDoH may exercise any remedies available to it as outlined in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, along with the required annexures, in accordance with these provisions, may result in the invalidation of the bid for the goods or services offered.

No agreement between the bidder and any third party will be binding on the NDoH.

5.1.5 SAMPLES TO BE SUBMITTED TO SAMPLE EVALUATION SITES

All bidders are required to submit samples, including those who are currently supplying the NDoH with products, to confirm the following:

- Compliance with the specifications set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines Act.

Failure to submit samples to both institutions listed below will result in the invalidation of the bid for the items offered. Samples must be submitted to each of the depots at the addresses indicated below prior to the closing date and time of the bid:



GAUTENG MEDICAL SUPPLIES DEPOT	CAPE MEDICAL DEPOT
Ms Pretty Nyokong Contract Manager Tel: 011 628 9001/11 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001

- No samples are to be sent to the NDoH.
- Samples should be clearly marked with the bid number, item number, and the bidder's name and address.
- All samples must be a true representation of the product that will be supplied.
- Bidders must submit at least one original pack of each offered item for evaluation.
- A mock sample may be accepted for a registered product with SAHPRA that is not yet available on the market. The mock sample must be a true representation of the product to be supplied, should a contract be awarded, and must include the product (tablet, capsule, liquid, etc.) in a form that may not be in the original container, along with the SAHPRA-approved artwork and package insert.
- It is the bidder's responsibility to ensure that samples have been received at the addresses provided above.
- All samples for awarded items will be retained for the duration of the contract.
- For **Schedule 6** medicines only, the primary packaging/artwork and package insert, or professional information must be submitted (do not include the product itself).
- Proof of sample submission, including a signed copy of the item list as received by the sample evaluation site, should be submitted with the bid documents by the closing date and time of the bid.
- All samples submitted should include an eligible package insert, QR code or professional information leaflet (as indicated in section 5.1.1) approved by SAHPRA.



- Both institutions will evaluate the samples submitted to ensure compliance with the specifications.

5.1.6 COMPLIANCE WITH SPECIFICATIONS

- Items must comply with the specification as detailed in the bid document.
- The Department reserves the right to award a product with a Specification Deviation.
- The 28-day dispensing pack size is currently being phased out. In the case of medicines for chronic conditions, pack sizes suitable for a 30-day treatment cycle are required.

Where a 30-day dispensing pack size is advertised, and a 28-day dispensing provided, no conversion factor will be utilised. Evaluation will directly compare the 30-day dispensing pack size with other options offered and will not be considered as a specification deviation. All bidders are encouraged to participate in this tender.

6. PHASE III: PRICE AND PREFERENCE POINTS EVALUATION

6.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS CLAIMED IN TERMS OF THE REVISED PREFERENTIAL PROCUREMENT REGULATIONS (PPPFA), 2022

Preference points will be evaluated and allocated in accordance with the revised Preferential Procurement Regulations of 2022, issued under sections 2 and 5 of the Act, which aim to promote:

- a) **Empowerment of Historically Disadvantaged Individuals (HDI)**, which refers to South African citizens who:
 - Were denied the right to vote in national elections prior to the introduction of the Constitution of the Republic of South Africa, 1983 (Act No. 110 of 1983) or the Constitution of the Republic of South Africa, 1993 (Act No. 200 of 1993) (referred to as "the Interim Constitution").



- Are female.
- Have a disability.

- b) **Promotion of specific Reconstruction and Development Programme (RDP) goals**, as outlined in section 2(1)(d) of the Act. These goals may include contracting with individuals or categories of individuals historically disadvantaged by unfair discrimination based on race, gender, and disability, and the implementation of programmes from the Reconstruction and Development Programme, as published in Government Gazette No. 16085, dated 23 November 1994.
- **Selected Goal:** The promotion of South African-owned enterprises, specifically ownership held by South African citizens in the bidding enterprise.

6.1.1. HDI AND RDP GOAL POINTS CLAIMABLE FOR THIS TENDER

- **HDI Promotion and points claimable:**

NO	DESCRIPTION	CLAIMABLE POINTS
1	Who had no franchise in national elections before the 1983 and 1993 Constitutions	4
2	Who is a female	2
3	Who has a disability	2

- **RDP Goal for this tender and points claimable:**

NO	DESCRIPTION	CLAIMABLE POINTS
1	The promotion of South African owned enterprises	2

6.1.2. HDI CLAIMS MADE IN SBD 6.1 MUST BE SUPPORTED BY EVIDENCE BASED DOCUMENTATION

To claim preference points the bidder must complete the SBD6.1 in full and in accordance with the requirements. If the SBD6.1 is not completed in accordance with the requirements no preference points will be allocated.



6.1.2.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS FOR HDI

Percentage (%) of HDI ownership held in the bidding enterprise, should be supported by share certificate and share register i.e. if four (4) points is claimable, then two (2) points will be allocated for 50% ownership.

NO	HDI DESCRIPTION	CLAIMABLE POINTS
1	Who had no franchise in national elections before the 1983 and 1993 Constitutions	4

Equity Ownership claims must be supported by substantiating evidence to be considered for points claimed in SBD6.1.

• **HDI Equity Ownership**

The following supporting documents are mandatory to substantiate claims made for HDI equity ownership:

- Certified copies of identification documents (IDs), and
- Certified copies of Share certificates, and
- Share statement/Share Register reflecting the total number of shares issued by the bidding enterprise and the shares held by each qualifying HDI.

• **HDI Equity Ownership through Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for HDI ownership within a Trust/ Employment Scheme or Similar:

- Certified copy of applicable Trust Deed, and
- Share certificate confirming ownership held by Trust in bidding enterprise, and
- Trust Deed indicating HDIs listed as Trustees and Beneficiaries, and
- Certified copies of identification documents (IDs) of qualifying Trustees and Beneficiaries.



NO	DESCRIPTION	CLAIMABLE POINTS
2	Who is a female	2

- **Female Ownership**

The following supporting documents are mandatory to substantiate claims made for female ownership:

- Certified copies of IDs, and
- Certified copies of Share certificate/s, and
- Share statement / Share Register reflecting the total number of shares issued by the bidding enterprise and indicating the shares held by South African female/s, and

- **Female Equity Ownership through Trusts / Employment Scheme or Similar**

Should female ownership be held through a Trust Deed / Employment Scheme, such female/s must be listed as trustee and a beneficiary of such Trust Deed/ Employment Scheme and also be actively involved in the management of the Trust Deed/ Employment Scheme.

- Certified copies of IDs

NO	DESCRIPTION	CLAIMABLE POINTS
3	Who has a disability	2

- **Individuals with Disability**

The following supporting documents are mandatory to substantiate claims made for ownership, by individuals with a disability:

- Certified copies of identification documents (IDs), and
- Medical Certificate detailing the nature and extent of the disability required, and
- Certified copies of the share certificate(s) held by HDI member/s with a disability.



- **Equity Ownership for individual with a disability in Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for HDI equity ownership held by individuals with disabilities, who are also trustees or beneficiaries:

- Trust Deed indicating listed HDI owner as trustees and beneficiaries, and
- Certified copies of identification documents (IDs), and
- Medical Certificate detailing the nature and extent of the disability required, and
- Certified copies of the share certificate(s) held by HDI member/s with a disability.

6.1.3. RDP GOAL: PROMOTION OF SOUTH AFRICAN OWNED ENTERPRISES

6.1.3.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS

Percentage (%) of ownership held by South Africans in the bidding enterprise, supported by share certificate and share register, will be used to calculate claimable points i.e. one (1) point allocated for 50% ownership.

6.1.4. POINTS CLAIMABLE

NO	DESCRIPTION	CLAIMABLE POINTS
4	The promotion of South African owned enterprises	2

- **RDP Goal**

The following supporting documents are mandatory to substantiate claims made for ownership by South African individuals:

- Certified copies of IDs, and
- Certified copies of Share certificate/s, and
- Share statement/Share Register reflecting the total number of shares issued by the bidding enterprise and indicating shares held by South Africans, and



- **RDP Ownership in Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for ownership in Trusts / Employment Scheme or Similar:

- Share certificate(s) reflecting ownership of the Trust / Ownership Scheme in the bidding enterprise.
- Trust Deed indicating those South Africans who are both Trustees and Beneficiaries and who are actively involved in the management of the Trust; and
- Certified copies of IDs the Trustees and Beneficiaries.

6.2. HDI CLAIMS IN CONSORTIUMS, UNINCORPORATED JOINT VENTURES AND PARTNERSHIPS

Entities forming part of a bidding enterprise, such as those within a consortium, unincorporated joint venture or partnership may claim preferential points for qualifying Historically Disadvantaged Individuals (HDIs).

To validate such claims, a certified copy of the signed agreement between the participating entities must be submitted with the bid. **This agreement must clearly outline:**

- The terms of the relationship,
- The percentage (%) stake of each entity in the bidding enterprise for the purpose of executing the tender.

The claim for preferential points must be aligned to the equity ownership held by qualifying HDI individuals within each participating entity of the bidding enterprise.

Where the partnership is constituted, for example, by two entities with a 60% and 40% stake towards the execution of a tender:

- the qualifying HDI individuals within the 60% partner, will contribute towards 60% of the preferential points that may be earned for the bidding enterprise.



- Likewise, the HDI individuals within the 40% partner may contribute towards the remaining 40% that may be earned for the bidding enterprise

Each participating entity may therefore only claim HDI points in direct proportion to its stake in the consortium, unincorporated joint venture or partnership, as confirmed in the formal agreement between the entities forming the bidding enterprise

Preferential points are allocated based on the extent of HDI equity ownership held and alignment with applicable Reconstruction and Development Programme (RDP) Goals.

6.2.1. FORMULAE - PREFERENCE POINT SYSTEM TO BE APPLIED IN THIS TENDER

6.2.2. FORMULA FOR PRICE (90)

The 90/10 preference point system will be applied in this tender to allocate points for price. This system is applied for acquisition of goods or services with a Rand value **above R50 000 000 (all applicable taxes included)**. The points for price shall be allocated in the following manner:

Responsive bids will be adjudicated by the NDoH on the 90/10-preference point system in terms of which points for price will be awarded to bidders based on:

- The bid price (maximum 90 points)

The following formula will be used to calculate the points for price:

$$Ps = 90 \left(1 - \frac{Pt - Pmin}{Pmin} \right)$$

Were

Ps = Points scored for price of tender under consideration

Pt = Price of tender under consideration

Pmin = Price of lowest acceptable tender



6.2.3. FORMULA FOR HDI PREFERENCE POINTS (10)

$$NEP = \frac{NOP \times EP}{100}$$

Where

NEP = Points awarded for equity ownership by an HDI

NOP = The maximum number of points awarded for equity ownership by an HDI

EP = The percentage of equity ownership of and HDI within the enterprise of business, determined in accordance with the Act and specific provisions contained in the revised Preferential Procurement Regulations, 2022.

7. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The NDoH reserves the right to consider locally produced products offered by bidders. Bidders must indicate the manufacturing location of the products in the Excel Bid Response Document.

To provide preference to locally produced products, the definition of a "locally produced product" is limited to the formulation and conversion processes that use materials and components to manufacture medicines (including raw materials, whether imported or locally produced, for active pharmaceutical ingredients (API) and excipients to produce finished products) within the Republic of South Africa. A locally produced product includes the **fill and finish of sterile products** (vaccines small and large volume parenterals. However, it **excludes** the **fill, finish, and packaging of non-sterile dosage forms** such as solids, liquids, sterile drops, and semi-solid formulations.



Providing that awarding locally produced products does not compromise security of supply or affordability, the quantities allocated for award as locally produced products, may be allocated proportionally, aligning with the percentage of the product volume that will be locally produced.

Preference will be given to bidders of locally produced products if:

- A certified copy of the valid License to Manufacture, as per section 22C(1)(b) of the Medicines Act, for the local manufacturing site (including all applicable annexures) for medicines, complementary medicines, and medical devices/IVDs is submitted.
- The local manufacturing site is listed on the MRC issued by SAHPRA, indicating that the manufacturer is located in the Republic of South Africa.
- The Single Exit Price (SEP) published on the SEP database is not exceeded.
- The local manufacturer has demonstrated the capacity to supply the required volumes based on the data provided in the Excel Bid Response Document.
- The bidder complies with all other clauses contained in this SRCC.

If the necessary documentation or evidence is not included in the bid documents, the bid will not qualify for preference as a locally produced product.

8. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

9. SUBMISSION OF BIDS

All bid documents must be **compiled, indexed, and submitted** in the **exact sequence** specified. Each document must include the relevant annexure, as indicated in the bid document checklist (**Annexure A**) attached to the bid pack.



- Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.
- All bid documents must be signed in the spaces provided within the document, preferably in permanent black ink.
- All bid documents must be initialled at the bottom of each page in the space provided with "Bidder's Signature...", preferably in permanent black ink.
- Where certified copies of original documents are submitted, bidders must ensure that the certification is original, signed, and dated by the Commissioner of Oaths.
- If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths.
- All SBD bid documents must fully signed and witnessed, where required, preferably in permanent black ink. All mandatory documents as specified in **Annexure A** must be valid at the time of bid closure. The NDoH will not accept updated mandatory bid documents after the bid closure date, unless the document was valid at the time of bid closure but is set to expire during the bid validity period. In such cases, an updated document may only be submitted if specifically requested by the Department.
- Bidders who do not comply with any of the mandatory requirements will be deemed non-responsive and may not be considered for evaluation.

10. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time in a sealed package.



The full name and address of the bidder, including the return address, the bid number, and the closing date, must be clearly indicated on the package.

The bid must comprise of:

- **Set 1** The original **Hard copy bid**, (signed legal documents, including all certificates and documents requested); bound with tabs indicating section as per Annexure A Checklist.
- **Set 2 (Electronic Copies)**, consisting of a scanned PDF of the Hard Copy bid, and saved together with Set 3 on a USB Flash Drive / Storage Device.
- **Set 3 (Excel Spreadsheets)** comprising of the electronically completed Excel spreadsheets.

All fields must be completed. Where the requested information / documentation is not applicable, indicate 'N/A' and provide a comment explaining the reason for non-applicability.

Set 1: Hard copy legally binding bid documents.

Bidders must complete all SBD, PBD and Bid Response forms in permanent black ink, or typed. Where no electronic entry field is provided, bidders must complete the forms in permanent black ink, handwritten. All bid documents must be signed in ink in the spaces provided within the document. All bid documents must be initialed at the bottom of each page.

The following must be applied:

- Where certified copies of original documents are submitted, bidders must ensure that the certification is original and dated by the Commissioner of Oaths.
- If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths. Where applicable, all bid documents must be witnessed preferably in permanent black ink.



- The signed hard copy of the bid document will serve as the legal bid document.
- Bidders must submit their complete bid in hard copy format (paper document).
- All pages in the complete bid document must be signed and initiated with preferably permanent black ink.
- The use of correction fluid is not acceptable.
- Any change/s must be clearly indicated and initiated.

Note Set 2 & 3

Bidders must submit a USB flash drive/storage device with a digital copy of the completed bid. Bidders must follow the same compilation sequence as per the index and use the index admin code abbreviation used in the file name.

Set 2: PDF of Hard Copy signed legal documents. (i.e., PDF of Set 1)

Bidders must submit a PDF version of the entire signed hard copy bid, including all certificates and documents requested.

Set 3: Electronic version of bid documents

In addition, bidders must submit the electronic versions, Bid Response Document, and other relevant spreadsheets in Excel (not PDF). All three sets of information must be submitted for the bid to be evaluated. Ensure that the bid price is offered for the product as specified.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.



11. LATE BIDS

Bids received after the closing date and time at the address indicated in the bid documents will not be accepted for consideration and, where practical, will be returned unopened to the bidder.

12. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

13. FRONTING

The NDoH supports the spirit of the RDP Goals and HDI empowerment and recognizes that true empowerment can only be achieved through individuals and businesses acting in accordance with the Constitution, and in an honest, fair, equitable, transparent, and legally compliant manner. In this regard, the NDoH condemns any form of fronting.

The NDoH encourages bidders to act with honesty during their bid preparation process. Should any fronting, bid rigging, or collusion practices be suspected, the NDoH reserves the right to conduct investigations to verify the accuracy of the representations made in bid documents. Any form of misrepresentation, corruption, or fraudulent practice identified on the part of the bidder may result in serious consequences as specified in the relevant regulations. These consequences may include prohibiting the offending bidder from conducting business with the public sector for a period not exceeding 10 years.



14. SUPPLIER DUE DILIGENCE

The NDoH reserves the right to conduct supplier due diligence prior to the final award. This may involve such steps as the Department, in its sole and absolute discretion, deems necessary to satisfy itself regarding, inter alia, the legal, compliance, financial, and operational status and condition of the bidder, supplier, and/or its affiliates (as the case may be).

This may include site visits to assess whether:

- The item is manufactured at the site specified in the bid documentation;
- The bidder has the capacity to meet their allocated or agreed demand.

15. COMMUNICATION

The NDoH reserves the right to communicate with bidders post bid closure and during the bid validity period, for the purpose of seeking clarification on documents submitted or extending the validity period of the bid, if necessary. All communication between the bidder and the NDoH must be conducted in writing. Any communication between a bidder and any government official or a person acting in an advisory capacity to the NDoH regarding this bid, during the bid validity period, is strongly discouraged.

Any communication between the NDoH and the bidder, after bid closure may not provide any such bidder with a competitive advantage.

Information obtained during clarification may be shared with relevant committees involved in the tender process, in accordance with applicable procurement protocols and competition regulations.



16. CONTACT DETAILS

Postal address

Directorate: Affordable Medicines

Private Bag X828

PRETORIA

0001

Physical address

Directorate: Affordable Medicines

Dr AB Xuma Building

1112 Voortrekker Road,

Block A Pretoria

Townlands 351-JR

PRETORIA

0187

Please use the following e-mail address for any queries relating to the bidding process:

- tenders@health.gov.za



SECTION B

17. CONTRACT PERIOD

The contract shall be for the period of three years starting 1 May 2026 to 30 April 2029.

18. PARTICIPATING AUTHORITIES

Participating Authorities on this contract are: Provincial Departments of Health and other entities as approved by the Accounting Officer:

- Department of Correctional Services;
- South African Military Health Services;

Provincial Departments of Health:

- Eastern Cape
- Northern Cape
- KwaZulu-Natal
- Mpumalanga
- Gauteng
- Western Cape
- Free State
- Limpopo
- North West

Other entities may request to participate in the contract during the contract period. Such requests will only be considered if the awarded suppliers agree and confirm in writing that the inclusion of additional participants will not compromise the security of supply. Participation by other entities is subject to the approval of the Chief Accounting Officer of the NDoH. Appropriate consultation and communication with the contracted suppliers will take place prior to any approval being granted.



19. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

The contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after the award of the contract.

Failure to meet this requirement will result in the inability to process payment for goods.

20. AWARD CONDITIONS

NDoH reserves the right to:

- Award the same item as a multiple award to various suppliers (two or more) to address high volume requirements, security of supply and product availability.
- Negotiate prices and minimum order quantities and volumes.
- Award an item with a specification deviation.
- Refrain from applying conversion factors when a 30-day dispensing pack size is advertised, and a 28-day dispensing pack size is offered.
- Combine the quantities and award only one item number, where applicable if an item is advertised as a single item but is included in a therapeutic class and is recommended for award within that class.
- Only award one item in a procurement class will be awarded but could be awarded as a split award.

In cases where the tender does not achieve the most economically advantageous price, the NDoH reserves the right not to award that item.



20.1. SPLIT AND MULTIPLE AWARDS

The NDoH reserves the right to issue split or multiple awards, where necessary, to facilitate security of supply. The following will be taken into consideration when contemplating a split or multiple award:

- Source of API and manufacturing site;
- Capacity to meet expected demand as per published estimates in the Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.
- The Minimum Order Quantity (MOQ) for split or multiple awards will be negotiated and aligned to the smallest acceptable value.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

CATEGORY	DIFFERENCE BETWEEN POINTS SCORED	RECOMMENDED PERCENTAGE SPLIT
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10



Where a split of **three (3) or more** bidders is contemplated, the total score of each will be applied in the following formula to determine the percentage (%) split for each bidder:

For example, the percentage split for the highest scoring bidder will be calculated as follows:

$$\% \text{ Split} = T1/(T1+T2+T3)$$

Where :

- T1 = Score of highest Scoring Bidder
- T2 = Score of second Highest Scoring Bidder
- T3 = Score of third Highest Scoring Bidder

20.2. THERAPEUTIC CLASS AWARDS

The *Policy for Classifying Medicines into Therapeutic Classes for Purposes of Therapeutic Interchange* (as published: https://www.health.gov.za/wp-content/uploads/2021/08/Therapeutic-Interchange-Policy_July2021_final.pdf; July 2021) defines a therapeutic class as a group of medicines that contain active ingredients with comparable therapeutic effects. Medicines within a therapeutic class may not necessarily belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may have different mechanisms of action, adverse reactions, toxicity, and drug interaction profiles. In most cases, however, these medicines exhibit similar efficacy and safety profiles when administered in equipotent doses for a specific indication.



The ministerially appointed National Essential Medicines List Committee (NEMLC) is responsible for formulating and revising the Standard Treatment Guidelines (STGs) and the Essential Medicines List (EML). Therapeutic classes are specified in the "Medicine Treatment" section of the national STGs, which lists a class of medicines followed by examples, such as HMG-CoA reductase inhibitors (Statins) – e.g., simvastatin. These therapeutic classes are designated when no member of the class offers a significant benefit over another for a specific indication. The NEMLC may designate therapeutic classes for a condition, where applicable.

Such therapeutic classes may be utilised during the contracting process to achieve the most economically advantageous contracts, maximize market volume, and increase competition, thereby offering potential cost efficiencies through robust competition. A single member from the therapeutic class may be awarded on the contract.

HP09-2026SD – Therapeutic Classes			
Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 1	Calcium channel blocker – low dose	Amlodipine 5mg tablet, 28/30 tablets vs Felodipine 5mg tablet, 30 tablets vs Nifedipine 30mg modified release tablet, 28/30 tablets	
Class 2	Calcium channel blocker – standard dose	Amlodipine 10mg tablet, 28/30 tablets vs Felodipine 10mg tablet, 30 tablets vs Nifedipine 60mg modified release tablet, 28/30 tablets	



HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 3	ACE-inhibitor - low dose	Benazepril 10mg tablet, 28/30 tablets vs Enalapril 10mg tablet, 28/30 tablets vs Lisinopril 10mg scored tablet, 28/30 tablets vs Perindopril 4mg scored tablet, 28/30 tablets vs Quinapril 20mg scored tablet, 28/30 tablets vs Ramipril 2,5mg scored tablet, 28/30 tablets vs Trandolapril 0,5mg capsule, 30 capsules	
Class 4	ACE-inhibitor - moderate dose	Benazepril 20mg tablet, 30 tablets vs Enalapril 20mg tablet, 28/30 tablets vs Lisinopril 20mg tablet, 28/30 tablets vs Perindopril 8mg tablet, 28/30 tablets vs Quinapril 40mg tablet, 28/30 tablets vs Ramipril 5mg tablet/ capsule, 28/30 tablets/capsules vs Trandolapril 2mg capsule, 30 capsules	



HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 5	Bisphosphonate	Alendronic acid 10mg tablet, 28/30 tablets vs Alendronic acid 70mg tablet, 4 tablets vs Risedronic acid 35mg tablet, 4 tablets vs Risedronic acid 5mg tablet, 28/30 tablets vs Risendronic acid 150mg tablet, 1 tablet	
Class 6	Alpha blocker - for BPH	Alfuzosin 10mg tablet, 30 tablets vs Doxazosin 4mg tablet, 30 tablets vs Silodosin 8mg capsule, 30 capsules vs Tamsulosin 0,4mg capsule, 28/30 capsules vs Terazosin 10mg tablet, 28/30 tablets	
Class 7	Alpha blocker - BPH (titration doses)	Doxazosin 1mg tablet; 30 tablets vs Silodosin 4mg capsule; 30 capsules vs Terazosin 1mg tablet; 28/30 tablets	
Class 8	Alpha blocker - for Phaeochromocytoma - low dose	Doxazosin 4mg tablet; 30 tablets vs Terazosin 10mg tablet; 28/30 tablets	
Class 9	Acetylsalicylic acid	Aspirin 100mg tablet, 28 tablets vs Aspirin 300mg scored tablet, 14 tablets vs Aspirin 81mg tablet, 28 tablets	



Special Requirements and Conditions of Contract HP09-2026SD

HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 10	Proton pump inhibitor (PPI) – Standard dose (28's)	Lansoprazole 30mg capsule, 28/30 capsules (Series 1) vs Omeprazole 20mg tablet/capsule, 28/30 tablets/capsules (Series 2) vs Pantoprazole 40mg tablet/capsule, 28/30 tablets/capsules (Series 3) vs Rabeprazole 20mg tablet/capsule, 28/30 tablets/capsules (Series 4)	Class 10 will be considered as a series with Class 11 and Class 12
Class 11	Proton pump inhibitor (PPI) - Low dose	Lansoprazole 15mg tablet/capsule, 28/30 tablets/capsules (Series 1) vs Omeprazole 10mg tablet/capsule, 28/30 tablets/capsules (Series 2) vs Pantoprazole 20mg tablet/capsule, 28/30 tablets/capsules (Series 3) vs Rabeprazole 10mg tablet/capsule, 28/30 tablets/capsules (Series 4)	Class 11 will be considered as a series with Class 10 and Class 12
Class 12	Proton pump inhibitor (PPI) – Standard dose (14's)	Lansoprazole 30mg capsule, 14 capsules (Series 1) vs Omeprazole 20mg tablet/capsule, 14 tablets/capsules (Series 2) vs Pantoprazole 40mg tablet/capsule, 14 tablets/capsules (Series 3) vs Rabeprazole 20mg tablet/capsule, 14 tablets/capsules (Series 4)	Class 12 will be considered as a series with Class 10 and Class 11



HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 13	Fibrates	Bezafibrate 400mg tablet; 28/30 tablets vs Fenofibrate 200mg capsule; 30 capsules vs Gemfibrozil 600mg tablet; 30 tablets	
Class 14	Cardio-selective b-blocker - high dose	Acebutolol 200mg tablet/capsule, 28/30 tablets/capsules vs Atenolol 100mg tablet, 28/30 tablets vs Bisoprolol 10mg tablet, 28/30 tablets vs Metoprolol 200mg tablet/capsule, 28/30 tablets/capsules	
Class 15	Cardio-selective b-blocker - standard dose	Acebutolol 100mg tablet/capsule, 28/30 tablets/capsules vs Atenolol 50mg tablet, 28/30 tablets vs Bisoprolol 5mg tablet, 28/30 tablets vs Metoprolol 100mg tablet/capsule, 28/30 tablets/capsules	
Class 16	Nitrates, short acting	Glyceryl trinitrate 0,5mg sublingual tablet, 50 tablets vs Isosorbide dinitrate 5mg sublingual tablet, 50 tablets	
Class 17	Angiotensin II receptor blocker - low dose	Candesartan 4mg tablet, 28/30 tablets vs Losartan 50mg tablet, 28/30 tablets vs Valsartan 40mg tablet, 28/30 tablets	



HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 18	Angiotensin II receptor blocker - standard dose	Candesartan 32mg tablet, 28/30 tablets vs Losartan 100mg tablet, 28/30 tablets vs Valsartan 160mg tablet, 28/30 tablets	
Class 19	Non-sedating antihistamine	Cetirizine 10mg tablet, 28/30 tablets vs Fexofenadine 120mg tablet, 28/30 tablets	
Class 20	Quetiapine - standard dose	Quetiapine 100mg modified release tablet, 90 tablets vs Quetiapine 100mg tablet, 90 tablets	
Class 21	Quetiapine - intermediate dose	Quetiapine 200mg modified release tablet, 60 tablets vs Quetiapine 200mg tablet, 60 tablets	
Class 22	Quetiapine - higher dose	Quetiapine 300mg modified release tablet, 60 tablets vs Quetiapine 300mg tablet, 60 tablets	
Class 23	PDE5-inhibitors	Sildenafil 20mg tablet; 90 tablets vs Sildenafil 25mg tablets; 4 tablets vs Sildenafil 50mg scored tablets; 4 tablets vs Tadalafil 20mg tablets; 4 tablets vs Vardenafil 5mg tablets; 4 tablets vs Vardenafil 10mg scored tablets; 4 tablets	



Special Requirements and Conditions of Contract HP09-2026SD

HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 24	Dopamine agonists for Parkinsons disease	Pramipexole 0,25mg tablet; 100 tablets vs Ropinarole 1mg tablet; 84 tablets	
Class 25	SSRI- low dose	Citalopram 10mg tablet, 28/30 tablets vs Escitalopram 5mg tablets, 30 tablets vs Sertraline 50mg scored tablets, 30 tablets	
Class 26	SSRI-standard dose	Citalopram 20mg tablet, 28/30 tablets vs Escitalopram 10mg tablets, 30 tablets vs Sertraline 100mg scored tablets, 30 tablets	
Class 27	DOACs - Loading dose	Apixaban 5mg tablets; 60 tablets (Series 1) vs Rivaroxaban 20mg tablet; 28/30 tablets (Series 2)	Class 27 will be considered as a series with Class 28
Class 28	DOACs - Prophylaxis	Apixaban 2,5mg tablets; 28/30 tablets (Series 1) vs Rivaroxaban 10mg tablet; 30 tablets (Series 2)	Class 28 will be considered as a series with Class 29
Class 29	HMG CoA reductase inhibitors	Atorvastatin 5mg tablet; 30 tablets vs Pravastatin 20mg tablet; 28 tablets vs Rosuvastatin 2,5mg tablet; 30 tablets vs Simvastatin 10mg tablet; 28/30 tablets	



HP09-2026SD – Therapeutic Classes			
Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 30	HMG CoA reductase inhibitor	Atorvastatin 10mg tablet; 28/30 tablets vs Pravastatin 40mg tablet; 30 tablets vs Rosuvastatin 5mg tablet; 28/30 tablets vs Simvastatin 20mg tablet; 28/30 tablets	
Class 31	HMG CoA reductase inhibitor	Atorvastatin 20mg tablet; 30 tablets vs Pravastatin 80mg tablet; 28/30 tablets vs Rosuvastatin 10mg tablet; 28/30 tablets vs Simvastatin 40mg tablet; 30 tablets	
Class 32	Thiazide Diuretics low dose	Hydrochlorothiazide 12,5mg tablet; 28/30 tablets vs Indapamide 1,5mg tablet; 30 tablets	
Class 33	Thiazide Diuretics standard dose	Hydrochlorothiazide 25mg tablet; 28/30 tablets vs Indapamide 2,5mg tablet; 30 tablets	

20.3. SERIES AWARDS

Items will be considered to be awarded in a series where:

Dose titration is required e.g. a single molecule in a class is awarded across all strengths and pack sizes to allow for incremental dosing. Such an approach is required to ensure seamless dose titration, simplify supply and distribution, support healthcare worker use and acceptance, and improve patient adherence.



The following items will be awarded in a series:

Item No	Items Specification
30	Apixaban 2,5mg tablets; 28/30 tablets [Items 30 + 31 will be considered a series]
31	Apixaban 5mg tablets; 60 tablets [Items 30 + 31 will be considered a series]
179	Lansoprazole 15mg tablet/capsule; 28/30 tablets/capsules [Items 179 + 180 + 181 will be considered a series]
180	Lansoprazole 30mg capsule; 14 capsules [Items 179 + 180 + 181 will be considered a series]
181	Lansoprazole 30mg capsule; 28/30 capsules [Items 179 + 180 + 181 will be considered a series]
239	Omeprazole 10mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]
240	Omeprazole 20mg tablet/capsule; 14 tablets/capsules [Items 239 + 240 + 241 will be considered a series]
241	Omeprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]
251	Pantoprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 251 + 252 + 253 will be considered a series]
252	Pantoprazole 40mg tablet/capsule; 14 tablets/capsules [Items 251 + 252 + 253 will be considered a series]
253	Pantoprazole 40mg tablet/capsule; 28/30 tablets/capsules [Items 251 + 252 + 253 will be considered a series]
295	Rabeprazole 10mg tablet/capsule; 28/30 tablets/capsules [Items 295 + 296 + 297 will be considered a series]
296	Rabeprazole 20mg tablet/capsule; 14 tablets/capsules [Items 295 + 296 + 297 will be considered a series]
297	Rabeprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 295 + 296 + 297 will be considered a series]
310	Rivaroxaban 10mg tablet; 30 tablets [Items 310 + 311 + 312 will be considered a series]



Item No	Items Specification
311	Rivaroxaban 15mg tablet; 42 tablets [Items 310 + 311 +312 will be considered a series]
312	Rivaroxaban 20mg tablet; 28/30 tablets [Items 310 + 311 +312 will be considered a series]

20.4. PROCUREMENT CLASS

A procurement class is a grouping of medicines that share the same or similar registered clinical indications. While these medicines may vary in composition, pack size, strength, dosage form, source, mechanism of action, and other pharmacological properties, they have not yet undergone therapeutic interchange review. This classification aims to support the supply chain in adapting to market availability fluctuations to ensure continued access. Only one item within a procurement class will be awarded, though a split award remains a possibility.

Procurement Class	Members of the procurement class
Class 1	Acetylcysteine 200mg tablet; 20/25 tablets Vs Acetylcysteine 600mg tablet; 10 tablets

20.5. REFERENCE PRICING

The following items, as specified in the table below, are published with reference price based on clinical review.

Item No	Item Description	Reference Price
209	Methylphenidate 18 - 20mg modified release tablet/capsule; 30 tablets/capsules	R64.15
210	Methylphenidate 27 - 30mg modified release tablet/capsule; 30 tablets/capsules	R96.22



Item No	Item Description	Reference Price
211	Methylphenidate 36 - 40mg modified release tablet/capsule; 30 tablets/capsules	R128.29

20.6. NEGOTIATIONS

The NDoH reserves the right to negotiate prices, minimum order quantities, and supply volumes with bidders prior to the award of the contract. The negotiation process will be conducted at the discretion of the NDoH and in a manner it deems appropriate.

Proposed minimum order quantities (MOQs) should facilitate direct delivery to health establishments.

Where applicable, if an item is advertised as a single item but is included in a therapeutic class and is recommended for award within that class, the Department reserves the right to combine the volumes and award only one item number. In such cases, the Department will negotiate the awarding of combined volumes with the preferred bidder/s.

In addition, the NDoH reserves the right to review prices, minimum order quantities, and supply volumes with successful bidders after the contract award, as part of the contract management process. For more information on price adjustments based on systematic review refer to section 22.

20.7. NON-COMMITMENT

The NDoH reserves the right not to award, in part or in full. The Department also reserves the right to withdraw or amend any of the bid conditions, by providing notice in writing to all bidders prior to the closing of the bid or post-award.

If an incorrect award has been made, the NDoH reserves the right to remedy the matter in any manner it deems fit, including the cancellation of the contract.



21. POST AWARD CONDITIONS

Regulation 16(A)6.6 of the Treasury Regulations, issued under the Public Finance Management Act, 1999 (Act No. 1 of 1999), allows the Accounting Officer of a department, constitutional institution, or public entity to request participation in any contract arranged through a competitive bidding process by any state organ. This participation requires written approval from both the state organ and the relevant contracted suppliers.

The NDoH may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns, and the availability of items registered in terms of the Medicines Act at the date and time of bid closure. In these circumstances, the NDoH reserves the right to cancel the contract for an item or adjust the quantity awarded based on projected changes in demand. The Department will notify the contracted supplier within a reasonable time of the expected change. However, where patient safety is a concern, these changes may be implemented with immediate effect.

22. PRICE REVIEW

The NDoH anticipates three types of price review processes that may be implemented during the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the local and international marketplaces.



22.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on the submission of a complete price breakdown per instructions below for all relevant products; and assessment of the rationality of this price breakdown by the NDoH.

22.2. INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components.
 - Active Pharmaceutical Ingredient/s (API);
 - Formulation;
 - Packaging;
 - Logistics (this includes transportation, warehousing, and distribution);
 - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The NDoH reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.



- Items for which price breakdowns were not presented in the prescribed format at the time of bid closure, will render such item(s) ineligible for price adjustments.

22.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE. Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn considering evidence of poor compliance with contractual obligations.

Base average RoE for this tender will be as follows, per currency:

CURRENCY	BASE AVERAGE RATES OF EXCHANGE AVERAGE FOR THE PERIOD 01 DECEMBER 2024 TO 31 MAY 2025
Rand per US Dollar	R18.45
Rand per Br Pound	R23.64
Rand per Euro	R19.83
Rand per Yuan Renminbi	R2.54
Rand per Indian Rupee	R0.21
Rand per Swiss Franc	R21.05
Rand per Australian Dollar	R11.65
Rand per Danish Krone	R2.65



Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 December 2024 to 31 May 2025 using the South African Reserve Bank published rates for the specific currency.

22.4. APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Official applications for price adjustment consideration must be submitted to the NDoH at cpapharma@health.gov.za before the submission deadlines specified in the tables below.

The application must contain the following information:

- Contract description;
- Date of application;
- CPA cycle applied for;
- Items to be considered for CPA (Item no, NSN and Description).

The application must be submitted on a company letter head, signed, scanned and submitted to the CPA mailbox (cpapharma@health.gov.za) no later than the submission date as indicated in the table below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price. With reference to paragraph 4.2, the supplier will only be eligible for contractual price adjustments up to the most recent Single Exit Price value as recorded in the National Department of Health (NDoH) SEP Database.



22.4.1. EXCEPTIONAL PRICE ADJUSTMENTS BEFORE START OF CONTRACT

The contracted supplier may apply for an exceptional price adjustment before the start of the contract. These will be activated if the absolute change between the base RoE and the six-month retrospective average RoE indicated in the table below fluctuates by more than 10%. This adjustment applies to eligible components subject to CPA price adjustments based on the bid closure price.

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
0.01	01 October 2025 – 31 March 2026	03 April 2026	01 May 2026

22.4.2. ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
1	01 May 2026 - 31 October 2026	03 November 2026	01 December 2026
2	01 November 2026 - 30 April 2027	03 May 2027	01 June 2027
3	01 May 2027 - 31 October 2027	03 November 2027	01 December 2027
4	01 November 2027 - 30 April 2028	03 May 2028	01 June 2028
5	01 May 2028 - 31 October 2028	03 November 2028	01 December 2028



22.4.3. EXCEPTIONAL PRICE ADJUSTMENTS DURING CONTRACT PERIOD

Contracted suppliers may request exceptional price adjustments during the contracted period according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three-month retrospective average RoE indicated in the table below fluctuates by more than 10%.

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
0.1	01 May 2026 - 31 July 2026	03 August 2026	01 September 2026
1.1	01 November 2026 - 31 January 2027	03 February 2027	01 March 2027
2.1	01 May 2027 - 31 July 2027	03 August 2027	01 September 2027
3.1	01 November 2027 - 31 January 2028	03 February 2028	01 March 2028
4.1	01 May 2028 - 31 July 2028	03 August 2028	01 September 2028
5.1	01 November 2028 - 31 January 2029	03 February 2029	01 March 2029

Suppliers who received exceptional adjustments will, thereafter, receive routine adjustments based on the average exchange rate over the preceding three months, rather than the standard six-month historical average. The specific periods used to calculate the average rate of exchange (RoE) for these adjustments are outlined in the table below:

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE POST EXCEPTIONAL ADJUSTMENT	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
1	01 August 2026 - 31 October 2026	03 November 2026	01 December 2026
2	01 February 2027- 30 April 2027	03 May 2027	01 June 2027
3	01 August 2027- 31 October 2027	03 November 2027	01 December 2027



REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE POST EXCEPTIONAL ADJUSTMENT	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
4	01 February 2028- 30 April 2028	03 May 2028	01 June 2028
5	01 August 2028 - 31 October 2028	03 November 2028	01 December 2028

22.5. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The NDoH reserves the right to review both local and international market prices to identify the lowest comparable pricing. Should this review reveal prices lower than those stipulated in the contract, the Department may initiate price negotiations with the contracted supplier.

If the outcome of this negotiation is deemed unfavourable, the NDoH reserves the right to terminate the award for the item in question.

23. QUALITY

Products and contracted suppliers must conform to the conditions of registration of the product in terms of the Medicines Act for the full duration of this contract. In the event that the product and or contracted supplier does not conform to the conditions of registration of the product, NDOH reserves the right to cancel the contract.

24. DELIVERY AND QUANTITIES

24.1. DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to at all times.



The initial lead time, as proposed in the bid response document, will be calculated from the date of award of the contract and **not** from the date of placement of the first order. This lead time may not exceed 75 calendar days from the date of award from when the contract circular signed by the National Department of health has been published.

Lead time within the contract period is defined as the time from the submission of the order to the supplier to the time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time may result in penalties being enforced, as per sections 21 and 22 of the General Conditions of Contract (GCC).

24.2. QUANTITIES

The quantities reflected in the bid are estimated and no guarantee, either explicit or implied, is given regarding the actual quantity that will be procured during the contract period. Fluctuations in monthly demand may occur.

The NDoH reserves the right to negotiate MOQs where necessary. In cases where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two months' demand for all items, in alignment with the needs of Participating Authority/Authorities.



SECTION C

25. SUPPLIER PERFORMANCE MANAGEMENT

Supplier performance management will be the responsibility of the Participating Authorities, with oversight from the NDoH. If supplier performance disputes cannot be resolved between the contracted supplier and the Participating Authority, the NDoH must be informed for corrective action.

The NDoH, in collaboration with Participating Authorities, will monitor the performance of contracted suppliers throughout the duration of this contract. This will include, but is not limited to, the following areas:

- Ongoing supplier performance monitoring through compliance visits
- Adherence to reporting requirements
- Attendance of quarterly supplier meetings
- Execution of orders and delivery performance
- Management of order cancellations and product substitutions
- Identification and correction of irrational or misaligned orders
- Delivery schedule adherence
- Assurance of continuity of supply

25.1. COMPLIANCE WITH REPORTING REQUIREMENTS:

Suppliers must adhere to the reporting schedule and mechanism established by the NDoH. At a minimum, suppliers must submit the following information in the specified format and mechanism, after receiving training provided by the NDoH:

- All transactional data relating to orders
- A monthly age analysis
- Production pipeline data and forecasts, including:
 - Number of units of the item available (stock on hand)
 - Number of units of the item in Quality Assurance, awaiting release



- Number of units of the item in the current month's production plan
- Status of outstanding orders

25.2 Suppliers will be required to attend compulsory quarterly meetings

The NDoH will schedule and hold quarterly meetings with contracted suppliers. These meetings will include, but not be limited to, a review of supplier performance and the forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain, benefiting both suppliers and Participating Authorities.

25.3 ORDER PLACEMENT AND DELIVERY:

- Orders will be placed as needed during the contract period, with delivery points specified by the relevant Participating Authority/Authorities.
- The instructions on the official order form regarding supply, dispatch, and submission of invoices must be strictly adhered to.
- Under no circumstances should the contracted supplier deviate from the orders issued by the Participating Authority/Authorities, unless written instruction is received from the relevant participating authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- A Participating Authority is under no obligation to accept any quantity that exceeds the ordered quantity.
- To facilitate the efficient implementation of the direct delivery strategy, contracted suppliers must pack orders according to the purchase order for the relevant health establishment.
- Only orders made using an official, authorized purchase order format are valid.
- Suppliers must acknowledge receipt of all purchase orders received from Participating Authorities in the manner stipulated by the relevant Participating Authority.



25.4 ORDER CANCELLATIONS AND SUBSTITUTION:

The Participating Authority/Authorities reserve the right to cancel any order if the lead time exceeds 14 days. In such instances, they may, at their discretion, procure supplies of equivalent quality and quantity as a substitute for the goods not delivered in accordance with the contract, in line with Section 21.6 of the General Conditions of Contract.

Should this occur, the Participating Authority may source the item from an alternative supplier, and any cost difference between the contracted supplier's price and the price of the substitute item will be for the account of the contracted supplier.

25.5 IRRATIONAL OR MISALIGNED ORDERS:

In cases where an order is received that appears to be irrational or misaligned with estimates, the contracted supplier must consult the relevant Participating Authority prior to processing the order.

In the event of short supply, incorrect delivery, or misaligned orders, the supplier must issue a credit note within 15 calendar days of receiving both the credit request and the relevant supporting documentation from the participating authority.

25.6 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions, and delivery instructions stipulated in the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the NDoH. The NDoH reserves the right to update these minimum data requirements as needed (Annexure B).
- Invoices must clearly reflect both the "proprietary name" (brand name/trade name), which is unique to a particular medicine and approved under section 15(4) of the Medicines Act, and the item description as it appears in the contract circular and Master Health Product List (MHPL).



- The supplier must ensure that products are delivered in accordance with the appropriate storage conditions, as per the product's conditions of registration. Delivery is deemed complete upon signature of receipt by the delegated official.
- Any discrepancies between the invoice and the physical stock, or damaged stock, must be reported to the contracted supplier within a reasonable time, or as otherwise arranged with the supplier. This time period should allow for verification of the quantities received upon delivery.

Contracted suppliers will be responsible for the collection of goods delivered erroneously or in an incorrect condition, as formally arranged in consultation with the Participating Authorities. The Participating Authorities may recoup any expenses associated with the failure to collect such goods in accordance with the agreement.

25.7 CONTINUITY OF SUPPLY

Contracted suppliers must maintain at least two months' supply of the estimated quantity at the start of the contract and ensure a continuous supply throughout the contract's duration. If order fulfilment for a specific item deviate by 20% from the average monthly estimate for three consecutive months on a rolling basis, suppliers must notify the NDoH/Contract Management Unit (CMU) within two weeks of becoming aware of the discrepancy. In such cases, the supplier should engage with the NDoH and the relevant participating authority to update the demand forecast, align supply volumes accordingly, and prevent supply challenges.

Suppliers are expected to engage regularly with Participating Authorities to review demand and plan proactively to ensure uninterrupted supply.



Contracted suppliers must promptly inform all participating authorities and NDoH of any circumstances that may result in an interrupted supply, including but not limited to:

- Regulatory actions that may impact their GMP status or the status of entities on which they rely;
- Anticipated issues with the availability of active pharmaceutical ingredients (API);
- Industrial actions;
- Challenges with the manufacturing pipeline;
- Any other supply-related challenges.

Official communication regarding continuity of supply should be directed to stockalert@health.gov.za , as well as the Participating Authorities.

Official communication regarding payment challenges should be directed to medacc@health.gov.za , as well as the relevant Participating Authorities.

All official communications must include details of corrective actions taken by the contracted supplier to ensure continuous supply.

If the contracted supplier is unable to supply the awarded item, the supplier are required to source an alternative product that meets the same specifications.

In the case of a split or multiple awards, the alternative product must not be sourced from another contracted supplier for the same product. The alternative product must be supplied at the current price of the contracted item.



Prior to supplying an alternative product including items authorised for procurement utilising Section 21 and Section 26 of the MARSA or 101, the contracted supplier must seek approval from the NDoH and provide a sample to the two health establishments as outlined in section 5.4 of this SRCC. The contracted supplier must also provide the following information to the NDoH:

- Name of the product to be supplied;
- Quantities to be supplied;
- The period for which the product will be supplied. This provision applies only to emergency supply situations and cannot be used for routine or continuous supply.

If a contracted supplier is unable to supply the contracted item for a period **not exceeding six months**, the NDoH reserves the right to reallocate volumes proportionally to an alternative contracted supplier for the duration of the supply interruption.

If a contracted supplier is unable to supply a contracted item for a period **exceeding six months** for any reason, the NDoH reserves the right to cancel the contract, as outlined in Section 23 of the General Conditions of Contract (GCC), Clause 21.2.

Suppliers may be penalized for failing to meet the contractual lead time, as stipulated in Section 22 of the GCC.



26. REPORTING

The NDoH will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements. The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.

27. PACKAGING, LABELLING AND BARCODES

27.1. PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- All medicines must be supplied in complete, patient-ready packaging in the specified pack size, using containers that are properly sealed and labelled in compliance with Medicines Act. Packaging must be in a ready-to-dispense format that does not require any manipulation, packing, or repacking by the dispensing healthcare workers.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where the supplier recommends a particular stacking and storage configuration, this should be clearly illustrated on the outer packaging.



- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering.
 - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
- Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering.
 - The shipper pack must contain only one product, mixing multiple products in a single shipper is not allowed.
 - The outer packaging must be clearly marked as a "Part Box".

27.2. LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on both corners (length and breadth) all shipper packs, including any part boxes:
 - Item name as contained in the contract circular and the Master Health Product List (MHPL),
 - Registered product name;
 - Number of units in pack;
 - Batch number;
 - Expiry date;
 - Storage conditions;
 - Barcode.



- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g., thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly colored background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines Act.

27.3. BARCODES

- All unit and shipper packs should be marked with the appropriate barcode.
- The European Article Numbering Code 13 (EAN 13).

28. SHELF LIFE

- Unless SAHPRA has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
 - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry and,
 - Applications are approved by the Participating Authorities before execution of orders; and,
 - Upon notification of the remaining expired stock, such products will be collected and disposed of by the supplier at their own cost and,
 - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.



- If short-dated products are delivered without the undertaking, the following penalty formula will be applied for invoicing of short-dated products:
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept the product with a shelf-life of less than 12 months.

29. DISCONTINUATION OF CONTRACTED PRODUCT SUPPLY

It is the responsibility of the contracted supplier to ensure continuous supply of the contracted product until the end date of the contract, as stipulated in the Letter of Acceptance (SDB 7.1).

If the contracted supplier foresees a potential long-term interruption in supply, the supplier must submit a written letter to the Director-General of Health at least six months prior to the anticipated interruption. The letter must include the following:

- The reason for the long-term interruption.
- The impact this will have on the contract.
- The proposed solution or suggested way forward.

The supplier may only interrupt supply to a Participating Authority after informing the Director-General of Health and receiving written approval from the NDoH. It is the responsibility of the National Department of Health to communicate the outcome of this matter to the Participating Authorities.

If the contracted supplier decides to discontinue a contracted product with immediate effect, the Department reserves the right to source the item from an alternative supplier. If the price from the alternative supplier exceeds the contracted price, the supplier discontinuing the product will be liable for the price difference for a period of six months.



30. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

If a contracted supplier plans to merge with or be acquired by another entity, or intends to cede the contract to another supplier, the contracted supplier must inform the NDoH in writing as soon as they become aware of such an event.

Should the contracted supplier plan to cede a contracted item to another supplier, they must submit an official request in writing to the NDoH at least three months prior to the proposed effective date. The NDoH reserves the right to either accept or decline the request to transfer the contractual obligations to the new supplier under the current terms of the contract, or to cancel the contract altogether.

The contracted supplier is also required to inform the NDoH as soon as they become aware of any changes to their address, name, or contact details. These updates must also be reflected on the Central Supplier Database (CSD).

31. CANCELLATION OF CONTRACT

A request for the cancellation of a contract from a contracted supplier will only be considered if:

- A formal cancellation request in writing addressed to the Director-General: National Department of Health; and
- Evidence in support of the request is submitted.

The contracted supplier is obligated to continue supplying the contracted item under the existing terms and conditions of the contract until the NDoH has formally approved the cancellation request. Once approved, the NDoH will notify the Participating Authorities of the contract cancellation.

32. THIRD PARTIES

Participating Authorities will not make payment to or consult with a third party. No third party is entitled to put an account of a Participating Authority/Authorities on hold.

END